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ABSTRACT 
 
 
 
Development of a Biomarker and Clay Based Remediation  
 
Strategy for Populations at Risk for Fumonisin Toxicosis. (May 2012) 
 
Abraham Gay Robinson II, B.S., Prairie View A&M University 
 
Chair of Advisory Committee: Dr. Timothy D. Phillips 
 
 
 
Fumonisin B1 is the most prevalent congener of the fumonisin mycotoxins 
produced by Fusarium verticilliodies and is considered by many to be the most 
toxic.  Fumonisin B1 has been classified by IARC as a class 2B carcinogen.  
This is primarily due to evidence suggesting increased exposure to FB1 through 
contaminated foodstuffs is responsible for increased incidence of esophageal 
cancer in regions of China and South Africa.  Fumonisin B1 exposure has also 
been implicated in the increased incidence of neural tube defects along the 
Texas/Mexico border.  Therefore the principal goals of this research were to 1) 
Identify sorbent materials that would be compatible with the chemical 
characteristics of fumonisin B1 and evaluate their ability to sequester the toxin 
using established in vitro techniques; 2) evaluate urinary FB1 as a biomarker of 
exposure from a fumonisin contaminated diet; 3) utilize urinary FB1 as a 
diagnostic tool to evaluate the efficacy of NS in reducing biomarkers of FB1 
bioavailability in a Ghanaian population suspected to be co-exposed to 
aflatoxins and fumonisins.   
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Isothermal analysis and an alternative animal model were examined and 
compared to previously published results to determine the sorbent toxin 
interaction activity in vitro as a predictor of in vivo efficacy. An HPLC method for 
detection and quantitation of urinary FB1 was developed based on methods 
previously adapted for primary amine and biomarker analysis.  Urinary FB1 was 
evaluated as an HPLC detectable biomarker using a rodent model.  Calcium and 
sodium montmorillonite clays were selected to interact with the positive charge 
on FB1 at low pH and sorb the molecule.  Ferrihydrite was selected to interact 
with the negative charge on the FB1 molecule at neutral to high pH.  While both 
polarities of sorbent were effective, montmorillonite clays demonstrated a higher 
capacity for sorption of FB1 than ferrihydrite.  These in vitro results were 
confirmed in a rodent model where urinary FB1 was reduced 27% in NovaSil 
treated rats vs. controls.  Finally, in a Ghanaian population co-exposed to 
aflatoxins and fumonisins, urinary FB1 was significantly reduced at 2 time points 
when the NovaSil treatment was compared to placebo. 
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CHAPTER I 
INTRODUCTION 
 
 
1.1  Fumonisin B1 – The problem defined 
Mycotoxins are structurally diverse compounds produced by fungi that 
contaminate various agricultural commodities under pre-and post- harvest 
conditions. Tropical weather conditions including: high temperatures and 
humidity, excessive rains during harvest and flash floods lead to fungal 
proliferation and production of mycotoxins. Pre-harvest, harvest, and post- 
harvest practices and conditions; methods of transportation, marketing and 
processing; and insect damage all contribute to mycotoxin contamination 
(Wagacha, 2008). Although there are over 300 known mycotoxins, only a few, 
particularly those affecting cereals (maize, wheat, barley, oats, sorghum, rice) 
and groundnuts, are considered a significant risk to human health (Hussein and 
Brazel, 2001). These include aflatoxins, tricothecenes, fumonisins, ochratoxin, 
zearalanone, patulin and ergot alkaloids. (Pitt, 2000) (Table 1) This work will 
focus on the fumonisin toxins, specifically fumonisin B1 (FB1), a mycotoxin 
produced by Fusarium verticillioides and F. proliferatum.  Although the term 
“fumonisin” refers to more than 15 different structural analogs of fumonisin toxin 
(Marin et. al., 2004), this term will be reserved for describing only the B1 isoform, 
This dissertation follows the style of Toxicological Sciences. 
  
2 
TABLE 1 
   
Health effects of common mycotoxins 
   
   
Mycotoxin Affected Crops Health Effects 
   
Afaltoxins 
Peanuts, corn, wheat, rice, 
cottonseed, nuts, dairy, products Heaptotoxicity, bile duct hyperplasia, liver tumors 
   
Fumonisins Corn 
Leukoencephalomalacia, porcine pulmonary edema, esophageal cancer, 
hepatocellular carcinoma, Neural tube defects, liver cancer 
   
Ochratoxin A 
Wheat, barley, oats, corn, peanuts, 
cheese 
Tubular necrosis of kidney, porcine nephropathy, liver damage, 
teratogenesis, kidney tumors 
   
Patulin Apples, apple juice, wheat 
Brain and lung edema, lung hemorrhage, paralysis of motor nerves, 
antibiotic, carcinogenesis 
   
Trichothecenes (T-2, 
DON, 
diacetoxyscirpenol) Corn, wheat 
Digestive disorders, oral lesions, hemorrhage of stomach, heart, 
intestines, lung, bladder, kidney, edema 
   
Zearalenone Corn, hay 
Estrogenic effects, e.g., edema of vulva, uterine enlargement, testicular 
astrophy, abortion 
Adapted from the CAST report, 1989 
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the most common and toxic fumonisin species, unless otherwise specified 
(Figure 1; Table 2). 
 
1.2  Historical background 
The growth and production of maize or Indian corn likely originated in 
southern Mexico. Teosinte, a grass that dates back 9000 years, is considered to 
be the oldest maize and was found by archaeologists near the Central Balsas 
River Valley near Puebla, Mexico. Archeologists made this discovery based on 
the original work of Dr. George W. Beadle, a 1958 Nobel Laureate, whose 
original work comparing the genome of “modern maize” and teosinte lead to the 
familial link.  From there it was a search to find the oldest evidence of teosinte 
cultivation which lead archeologists to Mexico (Carroll, 2010). Surveys have 
shown that maize is grown in every suitable agricultural region of the world and 
that a crop of maize is being harvested somewhere around the globe every 
month of the year. Maize grows from latitude 58° in Canada and the former 
Union of Soviet Socialist Republics to latitude 40° in the Southern Hemisphere. 
Maize crops are harvested in regions below sea-level in the Caspian Plain and 
at altitudes of more than 4000 m in the Peruvian Andes (FAO, 1992) (Figure 2). 
Searches of literature suggest that some of the earliest cultivators of 
maize (teosinte) were the indigenous people in the Americas in the area now 
known as Oaxaca, Mexico. Maize was an essential item in Mayan and Aztec 
civilizations and had an important role in their religious beliefs, festivities and 
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Figure 1. Two-dimensional structure of the fumonisin back bone, 3-
hydroxypyridinium and tricarballylic acid.  
 
Fumonisin Backbone
3-Hydroxypyridinium (3HP)   Tricarballylic Acid (TCA) 
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TABLE 2 
        
Fumonisin toxin structural analogs 
        
Analog Side chains to the fumonisin backbone 
        
  R1 R2 R3 R4 R5 R6 R7 
        
FA1 CH3 NHCOCH3 H OH OH TCA TCA 
FA2 CH3 NHCOCH3 H OH H TCA TCA 
FA3 CH3 NHCOCH3 H H OH TCA TCA 
PHFA3a CH3 NHCOCH3 H H OH OH TCA 
PHFA3b CH3 NHCOCH3 H H OH TCA OH 
HFA3 CH3 NHCOCH3 H H OH OH OH 
FAK1 CH3 NHCOCH3 H OH OH TCA O 
FBK1 CH3 NH2 H OH OH TCA O 
FB1 CH3 NH2 H OH OH TCA TCA 
Iso-FB1 CH3 NH2 OH H OH TCA TCA 
PHFB1a CH3 NH2 H OH OH OH TCA 
PHFB1b CH3 NH2 H OH OH TCA OH 
HFB1 CH3 NH2 H OH OH OH OH 
FB2 CH3 NH2 H OH H TCA TCA 
FB3 CH3 NH2 H H OH TCA TCA 
FB4 CH3 NH2 H H H TCA TCA 
FB5        
FC1 H NH2 H OH OH TCA TCA 
N-acetyl-FC1 H NHCOCH3 H OH OH TCA TCA 
Iso-FC1 H NH2 OH H OH TCA TCA 
N-acetyl-iso-FC1 H NHCOCH3 OH H OH TCA TCA 
OH-FC1 H NH2 OH OH OH TCA TCA 
N-acetyl-OH-FC1 H NHCOCH3 OH OH OH TCA TCA 
FC3 H NH2 H H OH TCA TCA 
FC4 H NH2 H H H TCA TCA 
FP1 CH3 3HP H OH OH TCA TCA 
FP2 CH3 3HP H OH H TCA TCA 
FP3 CH3 3HP H H OH TCA TCA 
Adapted from Rheeder et al., 2002 
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Figure 2.  Food and Agriculture Organization of the United Nations global growth of maize.  The origin of maize is 
indicated by the star.  
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nutrition. They claimed that “flesh and blood were made from maize”.  These 
early civilizations made a type of oven- baked bread from maize that was eaten 
with fish, grasses and vegetables. This balanced diet likely prevented the 
symptoms that would later be associated with a diet based predominately on 
corn consumption (FAO, 1992; Karthikeyan and Thappa, 2002).   
The ancient Mayan and Aztec civilizations used lime and ash to create 
alkaline solutions in order to process maize in a process known as 
nixtamalization.  Nixtamalization was very important in the early Mesoamerican 
diet, as niacin (vitamin B3) is not bioavailable in unprocessed corn. Alkaline 
hydrolysis unbinds and releases niacin for utilization in NAD and NADH 
production. It is debatable, however, as to whether these early civilizations 
understood the full implications of their discovery outside of tortilla production 
(Harper et al, 1958; Christianson et al., 1968; FAO, 1992).  
  Christopher Columbus discovered cultivated maize in Haiti, where it was 
known as MAHIZ, a name perhaps originating from the Mayan people 
responsible for its diffusion.  Shortly thereafter, he introduced maize to Europe in 
the late 15th century, being grown in Spain as early as 1498.  Maize spread 
throughout Europe and became the staple of an unbalanced diet in many poorer 
countries due to its low cost. Despite its successful cultivation, the critical 
nixtamalization process was omitted.  Without the alkaline processing, maize 
lacked niacin bioavailability and malnutrition struck many areas where maize 
consumption had become dominant.  This nutritionally deficient disease was first 
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described by Casal in 1735 as “mal de la rosa” with classic symptoms of 
dermatitis, diarrhea, and dementia, with death as the eventual outcome 
(Karthikeyan and Thappa, 2002).  By the 19th century, pellagra epidemics were 
recorded in France, Italy, and Egypt (Marasas, 1996).  In 1881, Italian born 
botanist and mycologist Pier Andrea Saccardo hypothesized that a fungus found 
on moldy corn was the causative agent in the European pellagra out breaks.  
Saccardo identified the causative organism as Oospora verticillioides.  While 
Saccardos’s hypothesis was ultimately disproven, he helped lay the ground work 
implicating moldy corn in the pathogenesis of human and animal disease. Nearly 
50 years later, in 1922, Goldberger and Tanner first suggested that the 
symptoms associated with pellagra were caused by an amino-acid deficiency. 
(Karthikeyan and Thappa, 2002) 
In 1904, John Sheldon first identified Fusarium moniliforme from moldy 
maize in feed associated with animal diseases (Sheldon, 1904).  Although this 
anamorph name was used widely by plant pathologists throughout the twentieth 
century, Manns and Adams were the first to suggest that the Oospora 
verticilliodes, described by Saccardo and Fusarium moniliforme, described by 
Sheldon were identical (Manns and Adams, 1923).  In 1924, Wineland described 
the teleomorph of F. moniliforme as Gibberella moniliformis.  Realizing that 
these maize contaminants were identical, Nirenberg combined the above to form 
F. verticillioides/ G. moniliformis in 1976, which is the commonly accepted 
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nomenclature (Kriek, 1981). Research on the production and health effects 
caused by consumption of moldy corn followed shortly thereafter.  
 
1.3  Conditions leading to the growth of Fusarium fungi – The source of 
fumonisin B1 
Fumonisin has been known to contaminate wheat and cereal grains, but it 
is primarily found in maize (Marasas, 1995).  Fungi in the genus Fusarium are 
the most common causes of ear and kernel rot diseases of maize.  Historically, 
F. moniliforme had been reported as the most common pathogen causing 
Fusarium ear rot; currently, its synonym F. verticillioides is considered the 
predominant species, and it seems clear that some previous reports of F. 
moniliforme overlooked other fumonisin producing species such as F. 
subglutinans and F. proliferatum (Munkvold, 2003).  Fusarium ear rot is 
characterized by its diffuse white to pink cotton-like appearance on the ear. In 
many instances, infected kernels are scattered around the cob among healthy-
looking kernels and display white streaks, in a starburst appearance, on their 
surface. These symptoms of corn infected by F. verticillioides are identical to 
those seen in F. proliferatum, and F. subglutinans contamination. Occasionally, 
these symptoms are also associated with contamination by other Fusarium 
species. 
Gibberella ear rot or “red ear rot” usually initiates from the tip of the ear 
and develops a red or pink mold covering a large proportion of the ear. Usually, 
10 
 
it is caused by Fusarium graminearum. Gibberella ear rot predominates in cooler 
areas or those with higher precipitation during the growing season.  
Of the 13 species that are able to produce fumonisins, only those 
belonging to the Liseola section, especially F. verticillioides and F. proliferatum, 
have been associated with fumonisin contamination of agricultural products 
(Table 3).  The severity of ear infection has been shown experimentally to be a 
good indicator of fumonisin accumulation in corn ears inoculated with F. 
verticillioides (Marin et al, 2004). Among all the known fumonisins produced by 
Fusarium spp., FB1 is the fumonisin analog most commonly associated with food 
contamination and disease formation in animals and humans.  Environmental 
conditions are known to have a significant effect on Fusarium contamination and 
toxin production on cereals (Table 4). Two related factors that have an important 
impact on the activity of Fusarium section Liseola are water activity (aw) and 
temperature (Doohan et al., 2003). The aw of a food is defined as the ratio 
between the vapor pressure of the food itself, when in a completely undisturbed 
balance with the surrounding air media, and the vapor pressure of distilled water 
under identical conditions. A water activity of 0.80 means the vapor pressure of 
the analyte is 80 percent of that of pure water. In most situations, the water 
activity increases with temperature. Most foods have a water activity above 0.95 
and that will provide sufficient moisture to support the growth of bacteria, yeasts, 
and mold (US FDA,1984). 
  
11 
TABLE 3 
     
Fumonisin-producing Fusarium species, analogs produced, and the maximum yields of FB1, FB2 and FB3 reported for each 
species 
     
  
Maximum fumonisin level (mg/kg) 
for: 
Fusarium sp. Fumonisin analog(s) FB1 FB2 FB3 
          
Section Liseola     
F. verticillioides MP-A   FA1-3, FB1-5, iso-FB1, FAK1, FBK1, FC1,4, FP1-3, PH1a-b  17900 3000 2300 
F. fujikuroi MP-C FB1 21 NT NT 
F. sacchari MP-B FB1 7 NT NT 
F. proliferatum MP-D FA1-3, FB1-5, FAK1, FBK1, FC1,4, FP1-3, PH1a-b  31000 17000 5700 
F. subglutinans MP-E FB1 230 NT NT 
F. thapsinum FB1-3 30 5 5 
F. anthophilum FB1-2 610 35 NT 
F. globosum FB1-3 330 4 24 
     
Section Dlaminia     
F. nygamai FA1-3, FB1-5, FAK1, FBK1, FC1,4, FP1-3, PH1a-b  7200 530 140 
     
F. dlamini FB1 82 NT NT 
F. napiforme FB1 480 NT NT 
F. pseudonygamai FB1-2 Tr Tr NT 
F. andiyazi FB1 Tr ND NT 
     
Section Elegans     
F. oxysporum FC1,3-4, N-acetyl-FC1,iso-FC1, N-acetyl-iso-FC1, OH-FC1, N-acetyl-OH-FC1 NT NT NT 
F. oxysporum var. redolens FB1-3 300 6 0.9 
     
Section Arthrosporiella     
F. polyphialidicum FB1 500 NT NT 
NT, not tested. Tr, trace amounts (1 to 4 ng g -1) were detected. ND, not detected (<1 ng g -1). Adapted from Rheeder et al., 2002.
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Adapted from Doohan et.al., 2003; aw = water activity 
 
 
 
 
TABLE 4 
    
Fusarium fungi and mycotoxin production 
    
Toxin Species Substrates 
Optimum 
production 
conditions 
        
Type A tricothecenes [T-2 
toxin, HT-2 toxin, 
neosolaniol, 
diacetoxyscirpenol] 
F. sporotrichioides, 
F. poae 
Barley, 
oats, rice, 
wheat, 
maize 
Moderately warm 
and humid (20 - 
15C, aw = 0.990) 
Type B 
tricothecenes[deoxynivalenol 
(DON), 15 acetyl-DON, 
nivalenol (NIV)] 
F. graminearum, 
F. culmorum 
Barley, 
wheat, rice, 
maize 
Warm and humid 
(25-28C, aw = 
0.97) 
Zeralenone 
F. graminearum, 
F. culmorum 
Wheat, 
rice, maize 
Warm (17-28C) or 
temp cycles (e.g. 
25-28C for 14-15 
days, 12-15C for 
20-28 days) and 
humid (aw = 0.97) 
Fumonisins 
F. verticillioides, 
F. proliferatum, 
F. subglutinans Maize 
 
Cool to warm 
conditions and 
humid (15-30C, aw 
= 0.98) 
Moniliformin 
F. subgultinans, 
F. verticillioides, 
F. avenaceum 
 
Wheat, rye, 
barley, 
oats, maize
Warm 
temperatures (25-
30C) 
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 Studies have shown for a given temperature, aw seems to dictate the 
metabolic activity of F. verticillioides and F. proliferatum.  Between 15 - 30°C, an 
aw of > 0.88 is required for fungal germination, however, an aw > 0.90 is required 
for growth for the fungi.  The aw limit for FB1 production is >0.92-0.93, however, 
F. verticillioides and F. proliferatum prefer different temperatures for this 
production, 10-25°C and 10-35°C, respectively (Figures 3 and 4). Generally, 
optimal conditions for F. verticillioides growth and fumonisin production are 20-
25°C with a water activity of 0.95-1.0, however the same activity in F. 
proliferatum preferentially occurs at 15°C (Marin et al, 2004).          
 It is no coincidence that regions worldwide with tropical and subtropical 
climates report increased prevalence of Fusarium verticillioides contamination 
with some reporting increased incidences of esophageal cancer and neural tube 
defects attributed to fumonisin B1 exposure. Maize production methods have a 
significant effect on the incidence of Fusarium contamination leading to corn rot.  
Maize is typically grown in a short rotation with one or two other crops in crop 
production areas with little overall crop diversity. As a result, most fields where 
the maize is grown have some remnants of past corn crop in or on the soil, or 
such residue is present in nearby fields. This residue is the primary source of 
inoculum for infections of maize kernels (Smith and White, 1988). Fusarium 
species survive well on maize crop residue as mycelium or other survival 
structures. These Fusarium populations in the soil flourish on senescent maize 
tissues that are deposited there regardless  
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Figure 3. Isopleth showing the combined values of aw and temperature that limit FB1 production (1mg FB1/g mold), growth 
(0.1mm/day), and germination (10% conidia) of isolates of F. verticillioides.  An isopleth is a line drawn through all points of 
equal value for some measureable feature.  Adapted from Marin et al., 2004.  
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Figure 4. Isopleth showing the combined values of aw and temperature that limit FB1 production (1mg FB1/g mold), growth 
(0.1mm/day), and germination (10% conidia) of isolates of F. proliferatum.  An isopleth is a line drawn through all points of 
equal value for some measureable feature.  Adapted from Marin et. al., 2004. 
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of whether they were previously infected. Fusarium species can also colonize 
senescent tissues of other crop and weed species that are not considered hosts 
for these pathogens (Munkvold, 2003). 
F. verticillioides employs several maize infection pathways including silk 
infection, insect injury and systemic transmission from seeds or roots to kernels 
(Munkvold et al.,1997; Sobek and Munkvold, 1999). The relative importance of 
these infection pathways vary based on geographic region.  In the Midwest 
region of the U.S., severity of Fusarium ear rot and symptomless kernel infection 
are correlated with insect injury, primarily due to Ostrinia nubilalis, which 
appears to be the most important infection pathway in this area (Munkvold, 
2003). For reasons that are not entirely known, drought stress and insect 
damage to crops (especially corn) are inextricably linked. Furthermore, Fusarium 
ear rot severities have been correlated to wound size caused by insect damage 
in studies of experimental inoculation methods (Miller, 2001).   
The relative importance of lepidopteran insects (a large order of insects 
that includes butterflies and moths) in disease development caused by F. 
verticillioides versus F. graminearum can be illustrated by how insect control 
affects the success of the two pathogens. In the U.S., transgenic Bt maize 
hybrids, have been very successful in preventing damaged from insects 
(Bucchini and Goldmann, 2002). These hybrids, which are highly resistant to 
European corn borer moth injury, have much lower levels of Fusarium ear rot 
and fumonisins (up to 90% reduction), compared to conventional hybrids 
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(Munkvold et al., 1999). Bt hybrids have also been shown to have lower levels of 
DON (as a result of reduced F. graminearum infection), but the reductions have 
been more modest (up to 59% reduction) (Schaafsma et al., 2002).  A similar 
situation exists in Europe as reductions in deoxynivalenol, nivalenol and 
zearalenone were not as great as reductions in fumonisins when these insects 
were controlled with transgenic insect resistance in the field in France and Spain 
(Bakan et al., 2002).  It is believed that insect damage does not seem to be as 
critical in F. graminarium infection when compared to F. verticilliodes infection. 
Aside from insect damage, there are other significant pathways of 
Fusarium infection.  Secondary to insect injury, infection through silks has been 
shown to be a significant source of Fusarium ear rot and symptomless infection 
by F. verticillioides (and probably F. proliferatum and F. subglutinans) 
(Desjardins et al., 2002; Munkvold et al., 1997; Nelson, 1992).  Systemic 
transmission of the fungus seems to be of lesser importance, but reports of the 
frequency of this infection method vary widely (Desjardins et al., 1998; Munkvold 
and Carlton, 1997). There may be environmental conditions under which 
systemic transmission is more prevalent, but this has not yet been demonstrated 
(Figure 5).  
In addition to these exogenous biotic factors, endogenous biotic conditions 
may also have an impact on the growth and toxin production of Fusarium 
species.  These biotic factors include but are not limited to availability of growth 
substrates and competition from other organisms that have adapted to be 
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Figure 5.  Factors that contribute to Fusarium contamination of maize. Insect damage from Ostrinia nubilalis (B) is directly 
correlated to contamination of maize by Furarium verticillioides/ proliferatum. Fallen maize or other plants can act as a host 
for Fusarium spp. innoculum (A).  Maize hybrids with the Bacillus therogenesis gene have been effective in reducing 
contamination from Fusarium spp (C). 
B C
A
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successful in that niche (Miller, 2001).  The success or failure of competing fungi 
is dependant on temperature and water activity which influence growth and 
production of toxins.  The energy and material commitment required for 
Fusarium spp. to produce fumonisin is significant. It is plausible that resource 
expenditure for the production of these toxins by Fusarium spp. hinges on two 
functions: energy storage and protection from other organisms, although reviews 
of current literature have been unable to confirm or refute this hypothesis.       
 
1.4  Fumonisin B1 production by Fusarium spp. 
Fumonisin B1 contamination of cereal grains is an endemic problem 
(Shephard et al., 1996; Marin et al., 2004).  It was first identified in 1988 by 
Gelderblom et al. as a novel toxin produced by Fusarium moniliforme that had 
cancer promoting properties (Gelderblom et al., 1988) .  Since then, FB1 has 
been shown to be a secondary metabolite produced by multiple species of the 
fungal Genus Fusarium, but is predominantly produced by F. verticillioides and 
F. proliferatum. As previously mentioned, the conditions that lead to growth and 
proliferation of Fusarium spp. capable of producing FB1 may not necessarily 
lead to the production of the mycotoxin.  
The structural components of the A and B fumonisins were first described 
by Bezuidenhout in 1988 (Bezuidenhout et al. 1988).  Advances in technology 
have allowed further characterization of the components of FB1. Stable isotope 
labeling of fumonisin has shown that the backbone of FB1 is of polyketide origin;
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 predominantly due to the condensation of acetate. Studies feeding radio labeled 
amino acids to F. verticillioides corroborate the hypothesis of polykeitde 
synthesis versus a lipid biosynthetic method in ideal conditions for production of 
FB1 (ApSimon, 2001).  The methyl groups at C12 and C16 are derived from 
methionine; the tricarballylic acid side chains are derived from glutamic acid; and 
the amino group is derived from serine (Marin et al., 2004).    Oxygen moieties 
found in the FB1 molecule are derived from 2 sources: molecular oxygen is 
utilized for the oxygen containing moieties along the carbon backbone and water 
is used for the tricarballylic acid groups esterified at C14 and C15 (ApSimon, 
2001). Fumonisin production under stress conditions has yet to be analyzed as 
far as substrate utilization is concerned. 
 The stereochemical structure of FB1 was delineated from 1024 possible 
stereoisomers using reactive chemical analysis, x-ray crystallography, and NMR 
(ApSimon, 2001).  It was found to be structurally similar to Alternaria alternata 
lycopersici (AAL) toxin, the only naturally occurring non-fumonisin inhibitor of 
sphinganine N-acetyl transferase activity (Abbas and Riley, 1996). Although the 
lewis structure and skeletal formula for FB1 depict a molecule that is spread out, 
molecular modeling and energy minimization studies by Beier and Stanker 
indicate that the fumonisin molecule is most likely folded on its self to form a 
cage-like structure.  Intermolecular hydrogen bonding has been identified as the 
most likely explanation of this phenomenon.  The implications of this structural 
orientation on membrane interactions and intercellular transport have yet to be 
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determined (Beier and Stanker, 1997).  Structurally, fumonisins are very similar 
to endogenous sphingolipids and it is this resemblance that is believed to be the 
basis of their toxicity (Merrill et al., 1996).  
 
1.5  Fumonisin B1 toxicity and mechanism of action 
The mechanism of fumonisin B1 toxicity is complex and not fully 
understood. FB1 is known to produce a number of intracellular and structural 
changes in target cells due to its enzyme specific activity.  These changes are 
more marked in some species than others and are most likely the source of 
species specific pathology following exposure to fumonisin toxins.  Because of 
the diversity of these effects, an all encompassing mechanism of toxicity is 
currently unknown. 
 
1.5.1 Cellular effects of fumonisin B1 exposure 
Although the details of fumonisin transport have not been fully elucidated, 
these toxins are thought to gain entrance into hepatic and kidney cells through 
organic anion/cation transporters, which lead to their untoward effects.  Although 
no structural differences have been reported between organic transporters in 
human and animal species (suggesting toxin mechanistic similarity), variations in 
the concentration of these cell surface transporters may account for the 
differences in species sensitivity (Tachampa et al., 2008). These variations may 
be significant contributors in the development of species specific 
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diseases such as equine leukoencephalomalacia and porcine pulmonary edema 
after ingestion of FB1.  Once inside target cells, FB1 has been reported to cause 
a number effects including: moderation of apoptosis, disruption of cell signaling 
pathways, increased production of reactive oxygen species, activation of 
caspase 3, reduction of glutathione, increases in tumor necrosis factor – α, and 
moderation of interferon and interleukin production. (Stockmann-Juvala and 
Savolainen, 2008; Sweeney et al., 1998, Merrill et al, 2001; Panjarian et al., 
2008).  These effects are most likely a down stream result of the disruption of 
sphingolipid metabolism through the inhibition of ceramide synthase (Merrill et 
al., 1996; Smith and Merrill, 1995; Hannun et al., 1986). 
 
1.5.2 Inhibition of ceramide synthase by fumonisin B1 and derivative 
molecules  
Ceramide synthase (CerS) is the cornerstone enzyme involved in 
sphingolipid metabolism. CerS is responsible for the production of ceramide and 
complex sphingolipids from the simple sphingolipids sphinganine/sphingosine 
and fatty acyl-coAs of varying length (C16-C24) (Pewzner-Jung et al, 2006) 
(Figure 6).  Ceramide is involved in the intracellular and extracellular functions  
critical to the survival and activity of a cell including differentiation, growth 
promotion, proliferation, senescence, apoptosis, and necrosis (Kolestnick, 2002; 
Okazaki et al. 1989; Venable et al., 1995; Hetz et al., 2002; Adam et al., 2002; 
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Figure 6. Scheme of sphingolipid metabolism. Bioactive SL metabolites are 
highlighted in red. Sites of fumonisin B1 inhibition are highlighted in yellow which 
causes an increase in sphinganine highlighted blue. Cell membrane 
components and complex sphingolipids are highlighted in green. SPT, serine 
palmitoyl transferase; KDS, 3-keto-dihydrosphingosine reductase; DES, 
dihydroceramide desaturase; SPPase, Sphingosine phosphate phosphatase; 
CK, Cer kinase; C1PP, C1P phosphatase; SMS, Sphingomyleline synthase; 
PC, phosphatidylcholine; DAG, diacylglycerol; GCS, glucosylceramide 
synthase; GCase, glucosyl CDase.  CDas, Ceramidase. Adapted from Bartke 
and Hannun, 2009. 
 
Serine + palmitoyl CoA 
3-Keto-dihydrosphingosine 
Dihydrosphingosine 
(Sphinganine) 
Dihydroceramide 
Sphingomylelin 
Sphingosine 
Ceramide 
Glucosulyceramide
Lactosylceramide
Glycosphingolipids 
Sphingosine-1-phosphate
Ceramide-1-phosphate 
Galactosylceramide 
Ethanolamine-1-phosphate + 
Hexadecenal 
Lipids 
SPT 
KDS 
CDas CerS (LASS) 
Fatty acyl CoA 
DES 
SMase 
PC 
DAG 
SMS 
GCS GCase 
CK 
C1PP 
CDas CerS (LASS) 
SK 
SPPase 
S1P lyase 
Sulphatide 
24 
 
Obeid et al, 1993; Wang et al., 2005; Blazquez et al. 2000; Ruvolo, 2003; 
Heinrich et al, 1999).  
 In addition to its activities as a moderator of cellular function, ceramide 
also serves as a transient precursor molecule in the production of complex 
sphingolipids.  These complex sphingolipids are critical for the maintenance of 
membrane structure (especially microdomains such as caveolae), and serve as 
binding sites for extracellular matrix proteins as well as for some 
microorganisms, microbial toxins, and viruses.  These sphingolipids are also 
found in lipoproteins and other lipid-rich structures used in transport and 
signaling (Merill et al, 2001).  
Fumonisin B1 is known to exert its toxic effects through the inhibition of 
ceramide synthase (sphinganine/ sphingosine N- acetyl transferase) (Merrill, et 
al., 1993;Merrill et al, 1996; Desai et al, 2002; Riley et al., 1996).  Fumonisins 
are structural analogs of the sphingoid bases sphinganine (SA) and sphingosine 
(SO), posessing a similar, but not identical, aminopentol backbone structure 
(fumonisin B1 possesses a 20- C aminopentol while sphinganine/ sphingosine 
contain an 18-C aminopentol). Fumonisins are esterfied at the C14 and C15 
carbons with tricarballylic acid side chains, whereas SA and SO are not.  
Additionally, the C1 carbon is hydroxylated in sphinagnine/ sphingosine and not 
fumonisin B1. Despite these differences, there is enough similarity between 
fumonisins and sphingolipids to bind to ceramide synthase, but not enough for 
FB1 to be used as a substrate in natural form (Figure 7).  For this reason, direct 
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Figure 7. Two dimensional structures of fumonisin B1, aminopentol,  
sphinganine, and sphingosine.  (fumonisin B1 (A), aminopentol (B),  
sphinganine (C), and sphingosine (D)) Note the similarity in backbone structure. 
All of the above can be used as substrates by ceramide synthase except  
for FB1. Aminopentol  (B) is the product of base catalyzed hydrolysis of  
the FB1 tricarballylic acid esters due to the conditions in the maize  
nixtamalization process. 
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competitive inhibition of enzymatic activity is thought to be the major route of 
toxicity. In the current model of how fumonisin B1 inhibits ceramide synthase, the 
aminopentol backbone competes for binding of the sphingoid base substrate, 
whereas the anionic tricarballylic acids interfere with binding of the fatty acyl-
CoA (Desai et al, 2002; Merrill et al., 2001) (Figures 8 and 9).    
Merrill et al. demonstrated that FB1 most likely interacts with the binding 
sites for sphinganine and fatty acyl–coenzyme A (CoA) because its potency is 
influenced by the concentrations of both substrates (Merrill et al, 2001). Merrill 
also noted that removal of the tricarballylic acid side-chains decreased the initial 
effectiveness of ceramide synthase inhibition in vitro by approximately 10-fold. 
Moreover, FB1 was not found to be acylated by ceramide synthase, but removal 
of the tricarballylic acid sidechains (producing the aminopentol form of fumonisin 
B1 or AP1) converted this inhibitor into a substrate. This was only possible if AP1 
occupies the sphingoid-base binding site and leaves the fatty acyl–CoA binding 
site accessible. The product of the reaction involving fully hydrolyzed fumonisins 
(AP-1) and palmitoyl co-A is N-palmitoyl-AP1 (PAP1) which has interesting 
properties. It is has been shown to be an inhibitor of ceramide synthase in vitro 
and causes a greater increase in sphinganine in HT-29 cells than FB1 or AP1 
cause at comparable concentrations (Humpf et al., 1998; Desai et al, 2002, 
Seiferlein et al. 2007).  
Although the mechanism for the inhibition of ceramide synthase by N-
palmitoyl-AP1 (PAP1) is not known, the simplest explanation is that PAP1 
  
27 
 
                
Figure 8.   A model for the active site of ceramide cynthase and how fatty acyl-CoA and sphinganine interact 
electrostatically at sites to activate enzyme activity (A).  Hydrophobic interactions may also play a role n the 
production of (dihydro)ceramide (B).  Adapted from Merrill et al., 2001. 
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Figure 9.   A model for the active site of ceramide synthase and how FB1 mimics regions of both the sphingoid 
base and the fatty acyl-CoA substrates to interact electrostatically with ceramide synthase(A and B).  FB1 can not 
be acylated and simply acts as a competitive inhibitor.  Adapted from Merrill et al., 2001. 
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most likely interacts with the hydrophobic binding domains for the substrates and 
product.   As would be predicted from the increase in sphinganine, PAP1 is more 
toxic than FB1 or AP1 for HT- 29 cells. Together, these findings suggest that 
when AP1 is taken up by cells, it can be converted to a more potent (toxic) 
inhibitor of ceramide synthase (Merrill et al., 2001; Humpf et al., 1998; Desai et 
al, 2002, Seiferlein et al. 2007). This may account for the observation that 
ceramide synthase is inhibited much less by AP1 than FB1, yet toxic effects still 
occur. During in vivo toxicity experiments, Voss et al. found that feeding 
nixtamalized Fusarium moniliforme culture material (which contains AP1) to rats 
causes lesions in liver and kidney that are indistinguishable from those caused 
by consumption of a diet prepared from untreated (FB1-containing) culture 
material (Voss et al, 1996).   
Although the focus of our study was non-hydrolized FB1, the toxicity of 
AP1 warrants further investigation. The processing and preparation of food that 
results in the loss of tricarballylic side chains is a common practice in many 
regions of the world where maize is a staple, such as Central and South 
America where as much as 185 μg AP1 has been found per gram of tortillas 
(Merrill et al., 2001). The nixtamalization of maize common in latin american 
food preparation results in a base catalyzed hydrolysis of the tricarballylic acids 
from fumonisin.  An acid catalyzed hydrolysis of fumonisin may occur during the 
preparation of indigenous foods (kenkey) due to the fermentation process 
common in many African countries (Halm et al., 1996).  Ultimately whether 
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through acid or base catalyzed hydrolysis, amounts of AP1 are formed, and are 
subject to metabolic activity of ceramide synthase leading to the formation of N-
palmitoyl-AP1 and inhibition of cerS.  This is critical because risk assessment of 
fumonisin exposure currently focuses on parent FB1 in food and biomarkers of 
exposure (urinary FB1 and changes in sphingolipid ratio).  Little to no attention is 
given to the potential presence of AP1 in food and its FB1 mimicking effects in 
the absence of detectable FB1. 
Increases in free sphinganine following cerS inhibition is due to the 
enzyme serine palmitoyl transferase (SPT-1) possessing no mechanistic 
feedback tied to ceramide synthase or intracellular sphinganine increases.  SPT-
1 is known as the rate limiting enzyme in de novo ceramide synthesis. SPT-1 
continues to produce sphinganine as long as the precursor molecules are 
available regardless of the activity of downstream enzymes in sphingolipid 
metabolism.  This leads to the initial change in the intracellular sphingolipid ratio 
that normally favors sphingosine concentration over sphinganine.  This change 
is transient, as enzymes with complex sphingolipid catabolic abilities (ie, 
sphingmyelinases) are activated to break down complex sphingolipids into 
precursor molecules, notably ceramide and sphingosine.  The increase in 
sphingosine helps to restore the “proper” intracellular sphingolipid ratio (He et 
al.,2006).   
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1.5.3 Effects of ceramide synthase disruption 
Disruption of the de novo sphingolipid biosynthesis pathway due to 
inhibition from ingested fumonisin B1 can lead to a number of untoward effects.  
In humans, the most notable and widely recognized effect associated with the 
consumption of FB1 contaminated corn is the development of esophageal 
squamous cell carcinoma (Gong et al., 2009; Marasas et al., 1988; Syndenham 
et al., 1990; Hendricks and Parker, 2002).  Ceramide a product of de novo 
sphingolipid biosynthesis is intimately involved in the apoptotic pathway 
mediated by caspase 3.  The relationship between ceramide and caspase 3  has 
been demonstrated in vitro using human keratinocytes,  In these studies there 
was a lack of apoptotic activity following irradiation with ultraviolet light in cell 
dosed with FB1 or myriocin (a serine-palmitoyl transferase inhibitor).  The 
inhibition of apoptosis seemed to occur in a caspase 3- independent fashion 
(Uchida et al, 2003).  Fumonisin B1 has also been known to indirectly interact ( 
most likely through changes in the sphingolipid ratio) with other mediators of 
cellular mitogenic and apoptotic activity including protein kinase C, NF-κB, tumor 
necrosis factor –α.  These cellular affectors possess both cell growth and 
apoptosis responsibility and it is suspected that in this manner FB1 possesses 
both mitogenic and apoptotic capabilities.  FB1 related cellular changes have 
also been shown to interfere with mediators of the cell cycle including cyclin D1 
(Bondy and Pestka, 2000; Buchner, 2000; Soriano et al., 2005).  Early studies 
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with fumonisin B1 failed to identify any genotoxic activity, and for this reason FB1 
has not been classified as a complete or initiating carcinogen in humans.
  Following administration of a known genotoxin (diethylnitrosamine), 
however, FB1 was able to promote the induction of hyperplastic foci in rat liver. 
Based on this and similar work, FB1 is widely considered to be a promoter of 
neoplastic formation and as such has been classified in class 2B by IARC (IARC 
monograph, 2003).  This classification is also due to in vivo studies in which rats 
fed FB1 developed neoplasms in their kidneys and liver in the absence of 
another initiator.  Fumonisins have not been shown to have a significant effect 
on P53 or peroxisome proliferation, however fumonisin consumption has caused 
accumulation of fatty acids in the liver which are subject to lipid peroxidation, 
free radical formation and damage leading to neoplasm formation (Gelderblom 
et al, 1996).  
 
1.5.4 Hepatocellular carcinoma and the consequence of co-exposure to 
aflatoxin B1 and fumonisin B1 
Hepatocellular carcinoma (HCC) is the most common form of malignant 
liver cancer with an elevated incidence focused in developing regions of the 
world.  In 2002, it was estimated that there were 600,000 new cases of liver 
cancer, 82% of which occurred in developing countries.   Regardless of 
geographic region, diagnosis of HCC has an extremely poor prognosis due to its 
propensity to metastasize and form secondary tumor sites. The 5 year (1988-
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2001) survival rate in the US was 8%, 9% in Europe (1995-1999), and only 5% 
when developing regions of Africa and Asia were compared.    Of the numerous 
factors that contribute to the high incidence (diagnosed and un-diagnosed) of 
HCC, hepatitis infection was the most serious contributor.  It was estimated the 
carriers of the hepatitis B surface antigen are 100 times more likely to develop 
HCC than their sero-negative counterparts (Chuang et al., 2009).   
Mycotoxins, specifically aflatoxin B1 (AFB1), are also identified as 
significant risk factors for the development of HCC.  Aflatoxin B1 is known to be 
a potent liver carcinogen; acting as an initiator by forming adducts at the N7 
guanine of liver DNA and serving as a promoter, triggering inflammation in the 
organ.  This N7 guanine adduct can lead to the formation of a more stable 
aflatoxin formamidopyrimidine (AFB1-FAPY) adduct which is often found as a 
persistent mutation in populations chronically exposed to aflatoxins (Wild and 
Gong, 2010).  The synergism between HBV and aflatoxin exposure is 
demonstrated in populations that have an increased odds ratio of HCC 
compared to populations with hepatitis sans aflatoxin exposure (Kumagia et al, 
2009).  This is most likely due to AFB1’s activity as a potent, persistent initiator, 
while HBV acts as a potent promoter of carcinogenesis due to inflammation. 
There have been a number of studies describing the exposure to AFB1 in 
Africa, specifically the liver status and immune effects of AFB1 exposure in 
Ghanaians (Jolly et al, 2006).  AFB1 appears to be ubiquitous throughout West 
Africa with >95% of sampled populations possessing the AFB1-albumin
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biomarker of exposure (Wild and Gong, 2010).  Combined with the high 
incidence of HBV in Ghana, HCC is the most common cause of cancer related 
death in adult men and third highest in adult women (Wiredu and Armah, 2006). 
  Notwithstanding the contributions of AFB1 and HBV to the incidence of 
HCC in Ghana, there is evidence to suggest that there may be another 
significant contributor to the high levels of liver cancer.  In a study by Ankrah et 
al., although a large number of the participants demonstrated markers of liver 
inflammation, a significant difference between AFB1 exposed and non-exposed 
participants did not exist.  One notable result from this study was 29% of the 
AFB1 positive and 62% of the AFB1 negative participants with markers of liver 
inflammation also demonstrated indicators of bile duct hyperplasia/obstruction. 
(Ankrah et al., 1994).  This ductular hyperplasia phenomenon has been 
observed in rodent studies in which participants were exposed to fumonisin B1, a 
common food contaminant (Gelderblom et al, 1996).  While it is plausible, all be 
it unlikely,  that AFB1 could be involved in a mechanism that protects the liver 
from inflammation, it’s more likely that another toxin (such as FB1) contributed to 
the observed inflammation.  
 In a study by Kpodo et al., 53% of maize samples intended for maize 
consumption from Ghanaian markets were found to be co-contaminated with 
AFB1 and FB1 (Kpodo et al., 2000).   Co-exposure to multiple mycotoxins is a 
cause of concern because so many have been shown to be potent toxic agents 
with diverse effects and a synergetic nature.  In a recent study, McKean et al. 
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examined the effects of co- exposure to AFB1 and FB1 in both in vitro and in 
vivo models.  A significant synergistic effect was observed when the LD50 of the 
individual toxins were compared to their combined potency (Mc Kean et al., 
2005).  For this reason, co-exposure to AFB1 and FB1 should be investigated as 
a significant contributor to the prevalence of HCC in West Africa (Kumagia et al, 
2009). 
 
1.5.5 Species specific effects of fumonisin B1 exposure 
As evidenced by the complexity of fumonisin B1’s mechanism of toxicity, 
the species on which FB1 can exert its effects are no less varied.  Ingestion of as 
little as 5-10 ppm fumonisin B1 in horses has been shown to induce 
development of equine leukoencephalomalacia (ELEM) (Marasas et al., 1988; 
Kellerman et al., 1990; Uhlinger, 1997). Signs of ELEM include nervousness, 
wide-based stance, trembling, ataxia, paresis of the lower lip and tongue, 
anorexia, and hypodypsia. Although the exact mechanism responsible for the 
white mater necrosis of is unknown, it should be clear that a significant portion of 
neural tissue is composed of complex sphingolipids (i.e sphingomyelin).  
Catabolism of these complex sphingolipids in an effort to restore sphingolipid 
ratios could be a critical process in etiopathogenesis of ELEM. Additionally, 
there is evidence that suggests that ELEM may be due to species specific 
permeability of the blood brain barrier. In mice, intracerebroventricular infusion of 
FB1 lead to a focal upregulation of inflammatory mediators and changes in the 
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sphingolipid ratios similar to those seen in leukoencephalomalacia (Osuchowski 
et al, 2005).  Studies that investigate the involvement of intestinal microflora 
metabolism of FB1 in equid toxicity are warranted but lacking.   
 Swine, while seeming unrelated to the equids are also susceptible to FB1 
toxicity.  With the exception of horses, swine are significantly less resistant to the 
effects of FB1 ingestion than other foodstock animals.  Levels > 92ppm lead to 
development of porcine pulmonary edema.  In mammals, pulmonary edema is 
generally caused by either: left ventricular failure or increased pulmonary 
capillary permeability subsequent to injury of the alveolar endothelium and 
epithelium.  In studies evaluating the cardiovascular toxicity of FB1 in swine, left 
ventricular hypertrophy and pulmonary arterial hypertrophy were observed 
indicating pulmonary hypertension of some etiology.   
The exact mechanism by which pulmonary edema in swine develops is 
unknown (Hasachek et al., 2001; Fodor et al., 2008).  There is evidence that 
suggests that fumonisin B1 acts as a cardiotoxin through the increased 
production of TNF-α (He et al., 2001; Soriano et al., 2005).  TNF-α has been 
shown to have negative inotropic influences on cardiac tissue (Duncan et al., 
2007). Additionally, the disruption of sphingolipid metabolism by FB1 causes 
collapse of cell to cell junctions leading to disruptions in the endothelial barrier, 
which can cause “leaky” vessels (Ramasamy et al., 1995; Soriano et al., 2005).  
The increased permeability of the lung vessels coupled with the congestive heart 
failure induced by FB1 would lead to pulmonary edema.  Again, species specific 
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sensitivity most likely plays a significant role.  Other effects of fumonisin B1 
exposure in swine include decreased weight gain, changes in serum 
biochemical analytes, immunologic response suppression, and histopathologic 
lesions in liver and kidney (Harvey et al. 1995; Harvey et al. 1996).   
Despite theses species specific signs of fumonisin toxicity, changes in the 
kidney and liver are almost always seen as FB1 pathognomonically targets these 
organs regardless of the species evaluated.  Biopsy of liver and kidney tissue 
following administration of fumonisin B1 in horses and swine, demonstrate low 
level storage of the toxin and histopathological changes prior to any clinical 
changes (Hasachek et al., 2001; Fodor et al., 2008).  Experimentally, male 
Fisher 344 rats developed renal adenomas and carcinomas when consuming 
FB1 contaminated feed at 50ppm and higher.  Paradoxically, only female 
M6C3F1 mice developed hepatic adenomas and carcinomas (NTP, 2001).    
 In addition to its carcinogenic potential, FB1 has been implicated as the 
causative agent responsible for increased neural tube defects along the US/ 
Mexico border (Missmer et al, 2006; Graham et al., 2010).  Neural tube defects 
are birth defects of the brain and spinal cord and are classified into anterior and 
posterior (Barber et al., 1999). The most common neural tube defects are spina 
bifida, encepahlocele, and anencephaly. In spina bifida, the fetal spinal column 
fails to close completely during the first month of pregnancy. There is usually 
nerve damage that causes at least some paralysis of the legs. Encephalocele is 
characterized by sac-like protrusions of the brain and meninges through 
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openings in the skull. In anencephaly, much of the brain does not develop. 
Infants with anencephaly are either stillborn or die shortly after birth. Although 
there are many proposed explanations for these events, the common element 
between them is the involvement of folic acid and the folate receptor (Marasas et 
al., 2004; Solomons, 2007).  FB1 has demonstrated the ability to mediate folate 
receptor/transport disruption (Cabrera et al., 2004). Strategies to reduce the 
incidence along the Texas/ Mexico border have included monitoring for FB1 
contaminated food sources and folate supplementation (Graham et al., 2010).   
NTD incidence is not a problem that affects only developed countries.  
Populations in developing countries experience a high number of NTD’s caused 
by unavoidable consumption of FB1 contaminated foods. Some regions have 
strikingly high frequencies (compared to that for the general U.S. population of  
3/10,000 live births), such as 106 NTD/10,000 live births in Quetzaltenango, 
Guatamala, which has a mostly indigenous population that consumes high 
amounts of maize as their staple food (Nguyen et al., 2008; Marasas et al., 
2004). The most frequent defect noted from this population was 
myelomeningocele (a type of spina bifida).  In South Africa, high NTD incidences 
have been found in a rural Transkei district in the Eastern Cape Province (61/ 
10,000) and in rural areas in the Limpopo Province (35/10,000); in contrast, far 
lower incidence figures are reported in urban regions such as Cape Town 
(1.06/10,000), Pretoria (0.99/10,000), and Johannesburg (1.18/ 10,000).  High 
NTD incidence rates (57 to 73/10,000) have been reported in rural areas in the
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northern provinces of China. The inhabitants of both the Transkei region and the 
northern provinces of China are likely to be exposed periodically to high 
fumonisin levels as a result of the consumption of fungal contaminated maize 
(Marasas et al., 2004).  Reduction of FB1 consumption and enhanced prenatal 
care/ nutrition would most likely cause a significant reduction in NTDs worldwide. 
A lesser known and studied effect of FB1 exposure is mycotoxin mediated 
immune suppression.  In vitro and in vivo studies demonstrate that exposure to 
FB1 suppresses immune response in animals (Odhav et al., 2008; Bondy and 
Pestka, 2000). Much of the early work concerning fumonisin effects on the 
immune system were performed in poultry.  Poultry are relatively insensitive to 
fumonisin B1 and few effects of toxicity were observed below 75mg FB1 /kg feed 
during in vivo studies.  Ingestion of diets containing 25% or greater F. 
moniliforme culture content (by weight) caused depressed thymus weights and, 
depressed antibody responses to sheep red blood cells (SRBC) and Brucella 
abortus in chickens (Bondy and Pestka, 2000; Sharma et al., 2008).  It should be 
noted in these early studies that fungal culture materials was used instead of 
FB1 isolate and the associated effects of administration could be influenced by 
the presence of more than one toxin in the isolate material.  Turkey poults 
ingesting feed contaminated with F. moniliforme culture material containing 
fumonisins at levels of 100 or 200 mg/kg feed displayed lesions indicative of 
immunotoxicity, including diffuse thymic cortical thinning, mild bursal follicular 
atrophy, and mild splenic lymphocyte depletion (Li et al., 2000).
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Cattle and swine have been evaluated as ruminant and non-ruminant animal 
models of immune suppression, respectively.  In calves, ingestion of feed 
experimentally adulterated with fumonisin contaminated corn screenings 
containing up to 148 μg/g total fumonisins inhibited neutrophil migration but not 
phagocytosis or antibody-dependent cytotoxicity (Bondy and Pestka, 2000).  
Lymphocyte blastogenesis following phytohemagglutinin induction was 
suppressed in pigs given fumonisin-contaminated culture material for 28 days at 
levels as high as 100 mg FB1/kg feed (Harvey et al., 1996).  
 Only one study to date addresses the potential immunotoxicity of purified 
FB1 following ingestion in rodents. Tryphonas et al. administered FB1 by gavage 
at doses from 1 to 25 mg/kg body weight/d for 14 d to Sprague- Dawley rats. 
This treatment caused depressed responses to SRBC at the 25-mg/kg dose 
level, and a significant trend toward increased numbers of colony-forming 
bacteria in the spleens of rats experimentally infected with Listeria 
monocytogenes. There were no marked effects on spleen lymphocyte 
blastogenesis, calcium mobilization in lymphocytes, natural killer (NK) cell 
activity, or peripheral blood monocyte phagocytic activity (Tryphonas et al,, 
1997).  Conversely, in a study of the effects in isolated rodent splenic immune 
cells, exposure to FB1 caused an increased production of nitric oxide and 
increased proliferation in macrophages and T lymphocytes, respectively 
(Dombrink-Kurtzman et al., 2000). The implications of these immune effects 
have yet to be fully explored. 
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In humans, immune suppression has been demonstrated in isolated 
macrophages and lymphocytes (Odhav et al., 2008). Currently, there is no 
available literature directly connecting immune suppression to FB1 exposure in 
human populations. 
 
1.6  Regulation of fumonisin B1 exposure 
Because of the myriad of different diseases fumonisin exposure can 
cause following ingestion, the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) has recommended a provisional maximum tolerable daily 
intake (PMTDI) of 2 μg /kg b.w. for fumonisins B1, B2 and B3, alone or in 
combination.  This is based on an experimentally derived NOEL for fumonisin B1 
exposure and a safety/ uncertainty factor of 100. The US FDA has 
recommended maximum levels for fumonisins in human foods and in animal 
feeds that they consider achievable and sustainable with the use of good 
agricultural and good manufacturing practices (Tables 5 and 6). At 2 – 4 mg/ kg 
maize for humans and 5 mg / kg maize for horses, these levels are significantly 
greater than the level recommended by JECFA (IARC, 2003).  Although these 
recommendations are in place, socioeconomic conditions often force the citizens 
of less developed countries to consume whatever is grown regardless of the 
condition.  Economically sensitive, yet culturally acceptable solutions for 
reducing exposure to mycotoxins like fumonisin B1 are in high demand. 
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TABLE 5 
  
FDA maximum levels of fumonisins in human foods and animal feeds in the USA 
  
Product 
Total fumonisins 
(B1+B2+B3) ppm (mg/kg)
Human foods  
Degermed dry milled corn products (e.g., flaking grits, corn 
products (e.g. flaking grits, corn grits, corn meal, corn flour 
with fat content <2.25%, dry weight basis) 2 
Whole or partially degermed dry milled corn products (e.g., 
flaking grits, corn products (e.g. flaking grits, corn grits, corn 
meal, corn flour with fat content <2.25%, dry weight basis) 4 
Dry milled corn bran 4 
Cleaned corn intended for masa production 4 
Cleaned corn intended for popcorn 3 
  
Animal feeds  
Corn and corn by-products intended for:  
Equids and rabbits 5 
Swine and catfish 20 
Breeding ruminants, breeding poultry and breeding mink 30 
Ruminants > 3 months old being raised for slaughter and 
mink being raised for pelt production 60 
Poultry being raised for slaughter 100 
All other species or classes of live stock and pet animals 10 
Adapted from FDA, 2001a 
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TABLE 6 
    
Levels of total fumonisins (B1+B2+B3) in corn, corn by-products and the total 
ration for various animal species recommended by the FDA in the US 
    
Animal or Class 
Recommended 
maximum levels of 
total fumonisins in 
corn and corn by-
products (ppm; 
mg/kg) Feed factor 
Recommended 
maximum level of 
total fumonisins in 
the total ration 
(ppm) 
    
Equids 5 0.2 1 
Rabbit 5 0.2 1 
Catfish 20 0.5 10 
Swine 20 0.5 10 
Ruminants 60 0.5 30 
Mink 60 0.5 30 
Poultry 100 0.5 50 
Ruminant, poultry 
and mink breeding 
stock 30 0.5 15 
All others 10 0.5 5 
Feed factor is contribution of ingredient in feed 1.0 = 100%. Adapted from FDA, 2001c  
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1.7  Methods for reducing fumonisin exposure 
There are 2 types of strategies for reducing fumonisin exposure: pre-
harvest and post harvest.  Pre-harvest strategies encompass all of the methods 
used to reduce fumonisin contamination of maize while still in the field.  Post 
harvest strategies cover all methods of remediation once the toxin has been 
harvested.  Generally speaking, pre-harvest strategies tend to be less expensive 
to implement and easier to adapt to a specific region.  Examples of these 
strategies include the use of genetically modified (GM) crops to reduce insect 
damage and fungal contamination, implementation of more effective crop 
rotation practices, the development of environmentally responsible fungicides 
that target metabolism specific to mycotoxic fungi (Duvick, 2001; Brown et al., 
2005).  Implementation of GM corn plants has yielded success in controlled 
conditions.  The introduction of the Bacillus therogenesis (Bt) gene into corn, has 
produced a crop that is more resistant to insect damage and less likely to be 
infected by Fusarium mold (Bucchini and Goldmann, 2002).  Unfortunately, a 
crop that has been modified to produce its own pesticide presents another set of 
problems. There are numerous questions about what affects will be seen in the 
general population from consuming this corn/ pesticide combination, will target 
pest species eventually become resistant, and concerns about whether 
resistance will be passed on to other organisms, and how will introducing a 
foreign gene into a crop affect its yield/quality?  It is these and other societal 
concerns that have prevented the introduction of these GM crops in the market
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place in developing or developed countries (Parrott, 2010).   Enhanced crop 
rotation practices that reduce the ability of the soil based Fusarium primary 
innoculum might be of use, however in developing countries, the availability of 
fertile soils needed for proper rotation is most likely a limiting factor (Munkvold, 
2003).  Phenolic compounds have gained notoriety both for their anti-oxidant 
properties as well as endocrine disruption activity. Beekrum et al. described the 
use of naturally phenolic compounds such as chlorophorin, iroko, maakianin, 
vanillic acid, and caffeic acid in reducing fumonisin production by Fusarium by 
as much as 94% (Beekrum et al., 2003). These compounds are produced by a 
variety of plants and could serve as a sustainable method of fumonisin control.  
Currently, further testing on the toxicokinetics of compounds intended for use 
and methods of environmentally friendly production and isolation of these 
compounds are barriers to implementation. 
Post harvest strategies to control fumonisin contamination have not been 
successful to date.  Controlling the conditions in which maize is stored is a  way 
to reduce fumonisin production that occurs post harvest; however the facilities 
needed for such an undertaking are usually not economically feasible in the 
regions that would benefit most from their application. Ozonation of mycotoxins 
has been proposed as an effective means of detoxifying contaminated foods.  
Application of ozone was successful in detoxifying aflatoxin contaminated 
material, however, it demonstrated little to no effect on material containing FB1 
(McKeneziee et al., 1997).  Other strategies have targeted the C-2 amine, as it is 
46 
 
critical to fumonisin B1’s potency as a toxin.  Lemke et al. demonstrated that 
reacting the fumonisin B1 with sodium nitrite in acidic conditions caused the 
formation of a diazonium salt which lead to the formation of an FB1 diol (Lemke 
et al., 2001).  This product was found to be less toxic than unreacted FB1.  In a 
method also targeting the primary amine of FB1, Castelo et al. demonstrated that 
cooking fumonisin contaminated corn at high temps in the presence of glucose 
reduced the toxicity (Castelo et al. 2001). This was most likely due to the 
conjugation of the primary amine to glucose through the Maillard reaction 
described by Louis-Camile Maillard in the 1910’s (Rindernecht and Jurd, 1958).  
This glucose fumonisin reaction has been shown to partially decrease the 
toxicity of FB1 in swine (Fernandez-Surumay et al., 2004).  While novel in 
application, the infrastructure required for implementation in developing 
countries would be the limiting barrier of the above strategies.   
The use of food additives is an accepted practice in animal production.  
The application of materials generally regarded as safe for use as “food 
additives” in the reduction of aflatoxin bioavailability has garnered a lot of 
attention over the years. Phillips et al. first described the use of hydrated sodium 
calcium aluminosilicate (HSCAS) in protecting chickens from the effects of 
aflatoxin exposure (Phillips et al., 1988).  Subsequent studies from Grant and 
Phillips verified the hypothesis that HSCAS was a high affinity sorbent for 
aflatoxin requiring an interlayer for sorption (Grant and Phillips, 1998).  These 
studies helped lay the foundation for the testing and application of dioctahedral 
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smectite materials as sorbents for other mycotoxins.  A survey study by 
Avantaggiato et al. demonstrated that bentonite, a dioctahedral smectite, 
displayed a pH dependent reduction in bioavailability of fumonisin B1 in a 
simulated gastrointestinal model (Avantaggiato et al, 2005).  Aly et al. reported 
the ability of HSCAS to reduce the concentration of FB1 in malt extract by 
almost 92% (Aly et al., 2004).  Although these studies demonstrate promise, 
further studies focusing on the efficacy of smectites in binding fumonisins are 
lacking.   
 
1.8 Research objectives 
It has been established that exposure to fumonisins can result in a 
number of untoward effects in a number of different species.  Despite extensive 
research into the mechanisms of toxicity and hazard assessment of FB1 
exposure, a practical method of assessing individual exposure for the purposes 
of risk assessment has yet to be identified and fully accepted. Without individual 
exposure assessment, it is difficult if not impossible to assess the efficacy of any 
remediation strategy utilized in a fumonisin exposed population. 
On a related note, the efficacy of Novasil (NS), a smectite clay, in 
reducing the biomarkers of aflatoxin exposure in humans and animals is well 
documented.  The success of NS clay in preventing the symptoms of 
aflatoxicosis has led to the examination of the potential for fumonisin 
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sequestration through similar target-sorbent interactions.  Therefore the principle 
goals of this research were to:  
1) Identify sorbent materials that would be compatible with the chemical 
characteristics of fumonisin B1 and evaluate their ability to sequester the toxin 
using established in vitro techniques.  Isothermal analysis and an alternative 
animal model were examined and compared to previously published results to 
determine the sorbent toxin interaction activity in vitro as a predictor of in vivo 
efficacy. 
2) Evaluate urinary FB1 as a biomarker of exposure from a fumonisin 
contaminated diet.  An HPLC method for detection and quantitation of urinary 
FB1 was developed based on methods previously adapted for primary amine 
and biomarker analysis.  Urinary FB1 was evaluated as an HPLC detectable 
biomarker using a rodent model.   
3) Utilize urinary FB1 as a diagnostic tool to evaluate the efficacy of NS in 
reducing biomarkers of FB1 bioavailability in a Ghanaian population suspected to 
be co-exposed to aflatoxins and fumonisins.  Previously established methods 
were utilized to evaluate the fumonisin exposure status of a population known to 
be at high risk for mycotoxicosis. 
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CHAPTER II 
EVALUATION OF SORBENT MATERIALS FOR FUMONISIN B1 
REMEDIATION 
 
  Fumonisin B1, B2, and B3 isoforms have been reported in corn based 
food and commodities worldwide with FB1 identified as the most prevalent and 
toxic congener (Shephard et al., 1996; Marin et al., 2004; IARC 2003).  The 
primary source of exposure to FB1 is the consumption of contaminated food and 
feedstuffs by humans and animals.  Acute and chronic exposures to FB1 are 
major contributors in the eitopathogenesis of equine leukoencephalomalacia and 
porcine pulmonary edema (Marasas et al., 1988; Kellerman et al., 1990; 
Uhlinger, 1997; Hasachek et al., 2001; Fodor et al., 2008).  Chronic FB1 
exposures have been implicated in the formation of liver and kidney neoplasms 
in rats and mice as well as increased incidences of esophageal cancer in 
humans Gelderblom et al., 1996; NTP, 2001; Gong et al., 2009; Marasas et al., 
1988; Syndenham et al., 1990; Hendricks and Parker, 2002). Consumption of 
fumonisin contaminated products has also been associated with increased 
incidences of neural tube defects (NTD’s) and other teratogenic anomalies in 
populations that consume maize products as a staple of their diet (Nguyen et al., 
2008; Marasas et al., 2004).  The complete mechanism of FB1 toxicity is not fully 
understood; however, inhibitions of ceramide synthetase and folate transport are 
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well-defined (Merrill, et al., 1993; Merrill et al, 1996; Desai et al, 2002; Riley et 
al., 1996; Marasas et al., 2004). 
Common food production methods, such as nixtimalization and heat 
processing, do not significantly reduce the toxicity of fumonisins in corn and can 
lead to the production of more potent toxins (Bullerman et al., 2002; Humpf and 
Voss, 2004). Thus, alternative strategies have been proposed for the 
remediation of contaminated foodstuffs.  One strategy that has enjoyed a 
measure of success has focused on the prevention of Fusarium growth on corn 
plants through genetic resistance mechanisms (Bucchini and Goldmann, 2002; 
Munkvold et al., 1999). Alternatively, novel methods of fumonisin detoxification 
using heat, ozone, or oxidative and non-oxidative deamination have also been 
reported. These methods have yielded limited success (Lemke et al., 2001; 
McKenezie et al., 1997).  Recent efforts have focused on decreasing the 
bioavailability of mycotoxins in the gastrointestinal (GI) tract (i.e., 
enterosorption), however, sorption and reduction of bioavailability of FB1 to 
blood and target organs has not been previously demonstrated.  This may be 
attributed to the zwitterionic properties of the fumonisins, which lead to varying 
charge characteristics at different pH values.  With ingestion being the primary 
route of exposure, it would be desirable to have a safe enterosorbent material to 
effectively bind the fumonisins despite changes in pH throughout the GI tract.   
 Due to the zwitterionic charge characteristics of FB1, we investigated two 
representative classes of sorbent material to determine which charge found on 
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fumonisin B1 (positive or negative) could be exploited most effectively for 
sequestration.  2-Line ferrihydrite (FH) was selected as a potential sorbent 
based on the hypothesis that the positive surface charge of the sorbent would 
interact with the negatively charged “free” carboxylic acid moieties of the 
fumonisin B1 molecule.  Ferrihydrite is a naturally occurring meta-stable iron 
oxide that is produced when an Fe2+ containing soil is rapidly oxidized in the 
presence of crystallization inhibitors (i.e. organic matter) (Figure 10). 
Experimentally, FH can be produced by the rapid hydrolysis of an Fe III 
containing solution. FH is characterized based on the number of X-ray diffraction 
peaks (2-6) that appear during analysis which are directly related to its level of 
crystallization.  Due to both its small particle size and poor crystallinity, FH 
typically has a surface area greater than 200m2/ g (Shwertmann and Cornell, 
2000).  Ferrihydrite also has a high density of local or point defects, such as 
dangling bonds and vacancies.  These defects coupled with the pH of the 
environment directly influence the polarity of FH surface charge; below pH 8, FH 
exhibits a positive charge (Bigham et al., 2002).     
 Montmorillonite was selected as the negatively charged sorbent based on 
the hypothesis that its negative interlayer would interact with the protonated C-2 
amine group (at acidic pH) and sequester the toxin.  Montmorillonite clays are 
dioctahedral smectite clays in which a portion of the Al in the octahedral layer 
has been isomorphically substituted with Mg (Figure 11).  Due to this elemental 
substitution, there is a reduction in positive charge which is no longer sufficient 
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to balance the negative charge of the structural oxygen molecules.  This charge 
imbalance is a major contributor to the characteristic net negative interlayer 
surface charge found in montmorillonite clays.  This charge is balanced in nature 
by exchangeable cations; the amount of positive charge needed for equilibrium 
is referred to as cation exchange capacity.  Conditions conductive to the 
formation and stability of smectites in soil environments include high Si and Mg 
activity, basic pH and poor drainage which allow precipitation of the soil 
constituent.  Small particle size and the ability of the interlayer to expand 
promoting ion exchange result in a large surface area of 600-800 m2/ g in 
montmorillonite clays (Bigham et al., 2002).  Due to their polarity, large surface 
areas, and zwitterionic characteristics, FH and montmorillonite were targeted as 
potential sorbent materials for fumonisins.  
Thus, the primary objective of this study was to evaluate the ability of FH   
and montmorillonite to sequester and sorb FB1 from aqueous solutions in vitro 
and in vivo.  This objective was investigated using analytical methods well-
established in our laboratory to estimate the capacity of sorption and to predict 
safety and efficacy of selected materials. 
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Figure 10.  Three dimensional representation of ferrihydrite.  Ferrihydrite is a poorly ordered iron oxide with a pH 
dependant ability to sequester anions.   
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Figure 11.  Three dimensional representations of two 2:1 dioctahedral clays.  
Smectite clays possess an expanded negatively charged interlayer which is 
critical to their binding ability.   
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2.1 Materials and methods 
2.1.1 Chemicals and reagents 
Fumonisin B1, o-phthalaldehyde (OPA), methanol, 2- mercaptoethanol, 
sodium phosphate dibasic, and phosphoric acid were purchased from Sigma-
Aldrich Corporation.  Acetonitrile and sodium hydroxide were purchased from 
Fisher Scientific.  Hydrochloric acid and boric acid were purchased from TJ 
Baker.  Clay samples including sodium montmorillonite (SWY-2) and calcium 
montmorillonite (NovaSil) were obtained from the Clay Repository (University of 
Missouri, Columbia) or Engelhard Chemical Corporation, Cleveland, Ohio.  
Ferrihydrite (FH) was prepared in the laboratory according to methods described 
by Schwertmann and Cornell in 2000.  Heat collapsed clays were prepared by 
heating 100 mg samples to 200°C for 30 minutes, followed by 800°C for 60 
minutes. These were transferred and maintained in air tight containers prior to 
analysis.  Fumonitest wide bore immunoaffinity columns were purchased from 
VICAM. Test tubes were from VWR international (16 x 125 mm borosilicate 
glass) and used in conjunction with an IKA- VIBRAX- test-tube shaker.  HPLC 
sample vials were obtained from Supelco. Visualization of Hydra attenuata was 
performed using a Nikon microscope and Nikon MKII optic light.  Centrifugation 
of samples was performed using an International centrifuge Model UV from 
International equipment company; a Corning Pinnacle 530 pH meter and 
Corning “3 in 1” probe was utilized to determine pH.  Distilled, deionized water 
was used in all experiments (18mΩosm). 
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2.1.2 Fumonisin analysis using HPLC 
 FB1 analysis was performed using a Waters HPLC System with auto-
injection (Model 717A) and fluorescence detection (Model 2475).    Separation of 
FB1 was achieved using a C-18 column (Supelcosil LC-ABZ, 15 x 4.6 cm, 5 um 
particle size from Supelco, Bellefonte, PA) proceeded by a pre-column filter (RP 
– 185 u 7.5 x 4.6 mm).  FB1 was detected using the wavelengths 335nm 
excitation and 440nm emission. 
 
2.1.3 Preparation of mobile phase  
The mobile phase was prepared by combining 230 ml of 0.1M sodium 
phosphate dibasic solution with 770 ml of methanol. The pH of the 0.1M sodium 
phosphate solution was adjusted to 3.35 with phosphoric acid prior to mixing 
with methanol to equilibrium. The mobile phase solution was then filtered 
through Whatman nylon membrane filters (0.45um) and cavitated using 
sonication to remove gas from the solution. Mobile phase was transferred to a 1 
liter HPLC solvent bottle and sealed. 
 
2.1.4 Preparation of o-phthalaldehyde solution 
O-phthalaldehyde reagent solution was prepared according to Riley et al. 
with minor modifications (Riley et al., 1994).  A 3% borate solution was prepared 
and the pH was adjusted to 10.5 using sodium hydroxide solution (1M). The 
solution was stirred until the pH was stable.  OPA (5 mg) was dissolved in 100 ul 
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of methanol followed by the addition of 5 ul of 2-mercaptoethanol and 10ml of 
3% borate buffer. 
  
2.1.5 Calibration curve for fumonisin B1 detection 
Fumonisin standards were prepared for high and low concentration calibration 
curves (A and B, respectively).  All calibration curve samples were 
prepared with a 2 ml volume in the following concentrations: 100 ppm, 50 ppm, 
10 ppm, and 0 ppm FB1 for calibration curve A; 0 ppm, 10 ppm, 5 ppm, and 2.5 
ppm for calibration curve B.  Prior to injection, all samples were prepared in the 
following manner: an HPLC injection vial containing 100 μl of the FB1 sample 
was derivatized with 200 μl of freshly prepared OPA solution (Figure 12), sealed, 
and vortexed for approximately 20 sec.  The HPLC was programmed to inject 
100 ul of the sample with a run time of 10 min.   Data from these injections were 
recorded in a Microsoft Excel spreadsheet and XY scatter graphs were 
prepared. Linearity of the calibration curve was tested by observing the r2 value 
of the line (close to 1.00) formed by the points from each calibration curve.  
Because of the similarity of the low concentration sample set to the analytical 
concentrations in our experiments, the low concentration calibration curve was 
utilized as the standard for subsequent isothermal analyses. 
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2.1.6 Fumonisin B1 sorption by FH and SWY-2 at different pH values 
 A 100 ml stock solution of 4 ppm FB1 was prepared by dissolving 400 ug 
of FB1 in 100 ml ddH2O.  This solution was divided into two 50 ml aliquots, A 
and B.  Aliquot A was adjusted to pH 2 with HCl and labeled A. Aliquot B was 
adjusted to pH 7 with NaOH and labeled B.  Borosilicate tubes were filled with 
2.5 ml of the 4 ppm FB1 solution (A or B) and combined with sorbent (i.e., FH, 
SWY-2 and 50:50 wt/wt FH/SWY-2) in the following concentrations: 0.01%, 
0.02%, 0.05%, 0.1%, 0.15%, and 0.2%.  FB1 samples were prepared without 
sorbent to serve as non-treated pH controls.  Samples for analysis were 
prepared in triplicate. Tubes were agitated at 1000 rpm for 18 h at 25°C for 
equilibration.  After equilibration, tubes were centrifuged at 700 x g for 20 min.  
After centrifugation, all samples were prepared and analyzed using HPLC as 
previously described.  Standard FB1 peaks were identified manually with a 
retention time of 4.5 to 5.5 min.  Peaks were integrated by Waters Breeze 
software.  Peak areas of treated samples were compared to standards with 
similar pH.  The amount remaining in solution was calculated based on the peak 
areas and sample injection volume. Results were reported as mass FB1 toxin 
bound vs. mass of initial sorbent in the sample.  
 
2.1.7 Isothermal analyses of fumonisin sorption 
 Aqueous sorbent suspensions (1 mg/ml) of Ferrihydrite, NOVASIL, and 
SWY-2 were prepared.  Two 12.5 ppm stock solutions of FB1 were prepared and    
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Figure 12.  The reaction of the primary amine of FB1 with o-phthaladehyde.  (FB1 (A) and o-phthalaldehyde (B)). 
The reaction occurs in the presence of β- mercaptoethanol, forms the 1-thiol-2 alkyl isoindol fluorescent product 
that is detected using high performance liquid chromatography separation and fluorescence detection. 
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individually adjusted with HCl or NaOH to pH 2 or 7, respectively.  Triplicate 
samples (2.5 ml total vol.) were prepared in the following concentrations: 1, 2.5, 
4, 5.5, 7.0, 8.5, and 10 ppm by combining 12.5ppm FB1 stock solution, ddH2O, 
and 0.5 ml of sorbent suspension.  Samples were agitated and allowed to 
equilibrate at 4°C, 25°C and 37°C for 18 h.  A 10 ppm FB1 sample without 
sorbent was also prepared for calibration curve and linearity analysis.  Following 
equilibration and centrifugation, analysis was performed as stated previously for 
all samples.  
 
2.1.8 FB1 MEC determination in hydra 
 Hydra attenuata (HA) were cultured and maintained in our laboratory as 
previously described by Mayura et al. (Mayura et al., 1991). The minimum
effective concentration of FB1 or (MEC) resulting in a toxic endpoint (tulip stage 
or disintegration) was determined by placing 3 adult hydra in small Petri dishes 
containing 4 ml of hydra media combined with logarithmic concentrations of FB1 
from 0.1 ppm to 1000 ppm. The minimum effective dose (MEC) was then titrated 
based on the initial logarithmic findings. The hydra response to FB1 toxin was 
recorded at time points 0, 4, 20, 28, 44, 68, and 92 h.   
 
2.1.9 In vivo sorbent efficacy assay 
Hydra attenuata (HA) were cultured and maintained in our laboratory as 
previously described.  Hydra were fasted 24 h prior to testing and during 96-h 
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acute toxicity tests.  Triplicate hydra were placed in 11 Petri dishes each 
containing 4 ml of hydra media.  Hydra media was prepared with FB1 at 400 
ppm in 7 of the dishes to produce the toxic endpoint as determined by previous 
experiments.  The FB1 contaminated dishes were divided into 2 groups (3 per 
group) and used to evaluate the ability of the sorbents to protect the hydra from 
the effects of FB1 exposure.  One hydra dish was prepared without sorbent as a 
positive control for FB1 toxicity. In group 1, sorbent (FH, NS, or SWY-2) was 
allowed to equilibrate with toxin prior to being exposed to hydra.  In group 2, 
sorbent was not allowed to equilibrate with toxin prior to being exposed to the 
hydra. Sorbents were added to the hydra dishes based on a theoretical 
maximum FB1 binding capacity calculated from the Qmax of the respective 
sorbents.    In three of the remaining FB1 free petri-dishes, hydra were exposed 
to sorbent without FB1 in the media to evaluate potential sorbent toxicity.  One 
dish was maintained toxin and sorbent free as an absolute control (Figure 13).  
Hydra were monitored and toxicity was recorded as previously described.  
 
2.2 Results  
2.2.1 Fumonisin B1 sorption by FH and SWY-2 at different pH values 
Fumonisin B1 (FB1) is zwitterionic in nature. FB1 At acidic pH is 
protonated (and positively charged) at the amino group on C2 of the molecule. In 
this form, it is electrostatically attracted to clays such as SWY-2 and NovaSil that 
contain a net negative charge on their interlayer surfaces.  FB1 tends to interact 
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less with these surfaces at neutral to basic pH due to less positive charge on the 
molecule. Identifying sorbent materials capable of accommodating the pH 
change of the gastrointestinal tract in mammalian organisms from acidic in the 
stomach to neutral/slightly basic in the intestine and the subsequent change in 
the polarity of FB1 was the major objective of this study.  An initial sorption study 
was conducted to explore the potential of montmorillonite (SWY-2) and 
ferrihydrite (FH) as FB1 sorption materials.  In this study, 0.02% SWY-2 was 
shown to bind 94% of 4 ppm FB1 at pH 2.  At pH 7, however, SWY-2 was less 
effective and   sorption of FB1 (8.8%) was only shown at sorbent levels of 0.05% 
or higher (Figure 14).   
  At neutral pH, FB1 was significantly sorbed by FH and this interaction was 
probably due to interface of deprotonated carboxyl groups in the tricarboxyllic 
acid   moieties with the positive surface charge of the sorbent.  FH sequestered 
greater than 92% of the total FB1 at 0.05% sorbent levels at pH 2 and 7. (Figure 
2)  This sorption was comparable with SWY-2 binding at pH 2, but better than 
SWY-2 at pH 7.  From these results, SWY-2 was found to be the most effective 
sorbent for FB1 at pH 2.  Conversely, FH was an effective sorbent for FB1 at pH 
7 (Figure 14).  Further investigation was warranted to determine the binding 
capacity of these sorbents.  
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Figure 13.  Study design of the Hydra attenuata FB1 toxicity/sorbent protection assay.  The hydra depicted are 
representative of timepoint 0, prior to any effects from toxin or sorbent.  Dishes depicted with montmorillonite 
represent both SWY-2 and NS containing dishes. SWY-2 and NovaSil are trade names for our representative 
sodium and calcium montmorillonites, respectively.
FB1 400 ppm FB1 400 ppm FB1 400 ppm FB1 400 ppm 
Montmorillonite 
equilibrated 
Ferrihydrite 
equilibrated 
Montmorillonite 
non- equilibrated 
Ferrihydrite non-
equilibrated 
FB1 400 ppm 
MEC control Absolute Control Montmorillonite Ferrihydrite 
Group 2 Group 1 
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2.2.2 Isothermal analyses of ferrihydrite and montmorillonite 
Isothermal analyses were performed at 25°C to determine the maximal binding 
capacity of SWY-2 and FH.  Isotherm equations have previously been used to 
model the adsorption of compounds in aqueous solutions to solid surfaces and 
to provide estimates of their Qmax or maximal binding capacity (Figure 15).  
These modified equations are based on the original Langmuir equations that 
related the coverage or adsorption of molecules on a solid surface to gas 
pressure or concentration of a medium above the solid surface at a fixed 
temperature (Grant et al., 1998).  Initially, both sorbents were added at 0.02% 
but the sorbent concentration was too high to produce a saturation curve.  
Therefore, concentrations of SWY-2 and FH were titrated down to 0.004% for 
use in the isothermal analyses to derive accurate measures of capacity (Qmax).  
The Qmax values for SWY-2 at pH 2 and 7 were 0.13 and 0.03 mol FB1/kg 
sorbent, respectively (Figure 16).  The Qmax values for FH at pH 2 and pH 7 
were 0.02 and 0.09, respectively (Figure 17). 
SWY-2 and FH isothermal analyses were also performed at 4°C and 
37°C. SWY-2 was evaluated at pH2 while FH was evaluated at pH7.  Qmax 
values for SWY-2 were 0.22 and 0.09 at 4°C and 37°C, respectively (Figure 18).  
The Qmax values for FH were 0.08 and 0.21 at 4°C and 37°C, respectively 
(Figure 19). Based on these results, sorption of FB1 by montmorillonites 
appeared to be more thermodynamically favored when compared to binding of 
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Figure 14.  Results from the preliminary evaluation of ferrihydrite (FH) and montmorillonite (SWY-2) sorption of FB1 
at physiologically relevant pH.  
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Figure 15. Langmuir equation commonly used to fit isothermal adsorption data. 
QmaxKdCwq= 
Langmuir Model 
q = sorbate adsorbed (mol/ kg), Qmax = 
maximum capacity (mol/kg), Kd = 
distribution constant, Cw = equilibrium 
concentration of sorbate 
(1+KdCw) 
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Figure 16. pH dependent sorption of FB1 by SWY-2. This representative montmorillonite clay demonstrates pH 
dependent sorption of FB1. 
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Figure 17. pH dependent sorption of FB1 by FH. This representative iron oxide demonstrates pH dependent 
sorption of FB1. 
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Figure 18. Temperature dependent sorption of FB1 by SWY-2. Isothermal analysis of SWY-2 sorption of FB1 at 4°C 
(blue) and 37°C (red).   
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Figure 19. Temperature dependent sorption of FB1 by FH. isothermal analysis of ferrihydrite (FH) sorption of FB1 at 
4°C (blue) and 37°C (red). 
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FB1 to FH.  Interestingly, increasing the time that FH was allowed to mix in the 
suspension prior to toxin addition increased its binding capacity (Figure 16).   An 
increased mixing time of 12 hours vs. 30-60 minutes prior to the addition of FB1 
toxin yielded a significantly increased Qmax value of 0.09 vs. 0.044 at pH 7 and 
25°C.  This phenomenon may be due to the dissolution of FH aggregates 
leading to an increased surface area for sorption of FB1. No differences were 
observed in binding capacity when suspension mixing times for SWY-2 were 
altered. 
In order to determine whether there was a difference in binding capacity 
for sodium montmorillonite vs. calcium montmorillonite, an isothermal analysis of 
NovaSil (NS) was performed at pH 2 and pH 7 and 25°C (Figure 20).  NS 
displayed a Qmax of 0.130 at pH2 which is comparable to the SWY-2 Qmax of 
0.126. NS also showed a Qmax of 0.04 at pH 7. These Qmax values suggested 
similar preference to sorption of FB1 by calcium montmorillonite when compared 
with sodium montmorillonite at identical pH values.  Isothermal analyses were 
also performed on heat collapsed samples of NS and SWY-2 to determine if FB1 
sorption is dependent on the inner layer of the clays. 
  The isothermal analysis of the heated clays at pH 2 and 25°C revealed 
no measurable Qmax, suggesting that the collapsed interlayer of montmorillonite 
clay prevents FB1 from binding.  Based on these findings, it is probable that the 
interlayer of montmorillonite plays a significant role in the ability of 
montmorillonite clay to act as a sorbent for FB1.  
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Figure 20. pH dependent sorption of FB1 by NovaSil. This calcium montmorillonite clay demonstrates pH 
dependent sorption of FB1 similar to that of the sodium montmorillonite clay SWY-2. 
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2.2.3 Hydra attenutta toxicity and sorbent protection assay 
FB1 toxicity was confirmed through the use of the Hydra toxicity assay.    
Based on the toxin dilution results, the MEC needed to induce the toxic endpoint 
was 300 ppm.  In our hydra assay, 400 ppm was used as the standard to 
produce a toxic endpoint.  Montmorillonite (SWY-2 and NS) at 0.35% and FH at 
1.25% were added to the individual sample dishes based on the calculated Qmax 
of the respective sorbents. In this assay, only the hydra exposed to 400 ppm FB1 
displayed effects of toxin insult and reached the tulip stage in 28 h with 
disintegration occurring by 44 h.  FB1 exposed hydra treated with either FH or 
montmorillonite were protected from the toxic effects and remained viable 
throughout the 96 h duration of the study. These results suggest that the clay 
provided protection to the hydra by sequestering the FB1 from surrounding hydra 
media, thus lowering the bioavailability of FB1 below the level that was toxic to 
the hydra (Figures 21 and 22).   
 
2.3 Discussion and conclusions 
In summary, in vitro studies in our laboratory have demonstrated that both 
sodium and calcium montmorillonite clays interact with FB1 at low pH. The 
mechanism for this interaction is likely due to the negatively charged surfaces 
within the interlayer of these clays reacting with the protonated (and positively 
charged) amino group of the FB1 molecule. Sorption studies also demonstrated 
that FH is an effective sorbent material for FB1.   
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Figure 21.  Schematic illustrating the adult hydra response to a toxin and the grading system used to plot the 
results.  
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Ferrihydrite, SWY-2 and NS protect hydra from FB1 toxicity
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Figure 22.  Ferrihydrite, SWY-2, and NS protect hydra from FB1 toxicity.  Montmorillonite clay (NS and SWY-2) and 
ferrihydrite (FH) protected the hydra from the exposure to FB1.  Hydra that were not treated with montmorrilonite or 
ferrihydrite reached the toxic endpoint by the 28h. 
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This interaction is likely due to the interface of positively charged sorbent 
material with negatively charged tricarballylic acids on the FB1 molecule at pH 7. 
SWY-2, NS, and FH were protective against the effects of FB1 in the hydra 
assay.  Moreover, none of the tested sorbents produced untoward effects in the 
hydra during the assay at neutral pH.  
 Fumonisin B1 is a toxin that causes a variety of pathologic conditions in 
many different species.  It has been identified as a potential carcinogen and has 
been linked to the prevalence of esophageal cancer in South Africa and China.  
Exposure to FB1 has also been shown to cause liver and kidney carcinomas in 
rats and mice.  In addition to its carcinogenic effects, FB1 poses a significant 
threat as a teratogen via interaction with the folate receptor.  With so many 
potential effects attributed to FB1 exposure, the need for a novel intervention 
strategy for FB1 is highly warranted.   
The ability of selected materials to sequester FB1 and lower its 
bioavailability is influenced by the relative pH and temperature at which the 
FB1/sorbent interaction occurs. Preliminary studies in our laboratory showed that 
montmorillonite clays interact with FB1 at low pH. The mechanism for this 
interaction is likely due to the negatively charged surfaces within the interlayer of 
these clays reacting with the protonated (and positively charged) amino group of 
the FB1 molecule. Sorption studies also demonstrated that FH is an effective 
FB1 sorbent material at neutral pH. This interaction is possibly due to the sorbent 
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material attraction to the (deprotonated) and negatively charged tricarballylic 
acids on the FB1 molecule at pH 7. 
Montmorillonite clays (SWY-2 and NovaSil) and ferrihydrite (FH) were 
capable of sequestering free FB1 from an aqueous solution at pH 2 and pH 7, 
respectively, which was verified by HPLC analysis. Based on isothermal 
analysis, SWY-2 and NovaSil exhibited similar sorption capacity of FB1 at pH 2 
and pH 7.  Hydra were protected from the lethal effects of 400 ppm FB1 when 
sodium/calcium montmorillonites and ferrihydrite were added to the test dishes 
at concentrations of 0.35% and 1.25%, respectively.  Importantly, exposure to 
montmorillonite or FH produced no discernable toxic effects in hydra. Further 
work is warranted to confirm the protection conveyed by montmorillonite and 
ferrihydrite against FB1 exposure and the potential application of these materials 
as enterosorbents of fumonisins in the diet. 
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CHAPTER III 
EVALUATION OF URINARY FB1 AS A BIOMARKER OF FUMONISIN B1 
EXPOSURE AND NOVASIL EFFICACY IN A RODENT MODEL 
 
  Assessing the risk of fumonisin B1 (FB1) exposure has been a goal of 
fumonisin research since the toxin was first described in 1988 (Gelderblom et 
al., 1988).  Quality risk assessment has three major components: hazard 
identification, dose response assessment, and exposure assessment; without 
these, no realistic estimation of risk can be made (Faustman and Omenn, 2008).  
There are numerous studies that identify FB1 exposure as a global hazard.  One 
of the most comprehensive of these studies was performed by Shepherd et al. 
as part of a global risk assessment of fumonisin exposure.  This survey included 
a literature review encompassing reports of suspected exposure hazard from 
1985 to early 1995. Thirty-two laboratories from 32 countries submitted data for 
this review which utilized the most accepted methodology for fumonisin 
detection to date. From this study, it was confirmed that fumonisin B1 was a 
common contaminant of corn in developed and developing countries with levels 
of maize contamination ranging from 0-330 ppm in corn.  It is interesting that the 
highest level of FB1 contamination in this study was found in corn from the 
United States (Shephard et al., 1996).  Since 1996, there have been other 
studies confirming the hazard of FB1 exposure in Brazil, Cote d’ Ivoire, China,
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 Guatemala, Ghana, and Iran (Caldas, E.D. and Sliva, 2007; Sangare-Tigori et 
al., 2006; Xu et al., 2010; Torres et al., 2007, Kpodo et al., 2000; Ghiasian et al., 
2006).  These hazard assessments are important as they serve as the 
foundation linking potential fumonisin B1 exposure to its myriad of health effects 
in humans and animals.   
Fortunately, the presence of a hazard does not translate to danger unless 
an exposure occurs.  This principle has been the caveat of many reported health 
effects from suspected fumonisin B1 exposures worldwide.  For example, 
elevated incidence rates of esophageal cancer (EC) in regions of South Africa 
and China have been correlated to potential chronic exposures to fumonisin B1 
(Shephard et al., 2007; Sun et al., 2007).  These studies have examined the 
elevated morbidity and mortality data and the elevated EC rates have been 
strongly correlated with FB1 contamination of maize at levels as high as 155 
ppm in foods intended for human consumption (Chu and Li, 1994; Marasas, 
1995;  Rheeder et al., 1992; Syndenham et al., 1990).  While these data were 
compelling, to date there are no in vivo studies in which any form of esophageal 
hyperplasia was a consequence of FB1 exposure.  Additionally, evidence of 
individual exposure to FB1 was assumed and not definitive.  Although common 
sense suggests that the presence of FB1 in food and cancer development would 
be sufficient for the causal relationship, by definition, without evidence of 
individual exposure and a dose response assessment with esophageal cancer 
80 
 
as the end point, risk does not exist.  Thus the relationship between FB1 and 
esophageal cancer remains circumstantial and correlated at best.      
Aside from excretion patterns following oral and parenteral administration, 
relatively little is known about the toxicokinetics and toxicodynamics of fumonisin 
B1. FB1 is not significantly metabolized in vivo and >95% is excreted in the 
feces, with a considerable portion of absorbed FB1 being excreted in the bile. 
Significant efforts have been directed at establishing a physiologic marker or 
biomarker of FB1 exposure.  Previously, exposures to fumonisins were 
estimated by measuring concentrations of the agent or fungal producer in food, 
water, or other media with which a population was in contact. However, this 
external exposure was only a rough estimate for the internal exposure (agent 
dose or its metabolite at the critical target in the organism). Factors that 
influence this internal exposure or dose are bioavailability of the agent, 
variations in concentrations and routes of exposure, and individual variation in 
rates of metabolism, distribution, and excretion. All of these affect the 
concentration of the toxic agent at the target organ, which is the most important 
information for risk assessment. Thus, internal exposure is best measured by 
determining the concentration of the toxicant or its ultimate metabolite at the 
critical site in the target organ or by determining adducts with cellular 
macromolecules such as proteins, amino acids, DNA, or its bases. These 
markers are often readily available in experimental toxicology from animal 
experiments, but only occasionally from humans as they often require invasive
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 procedures such as biopsies. Therefore, more accessible body fluids or tissues 
are used, such as blood, urine, or adipose tissue, or adducts with
 macromolecules such as albumin or hemoglobin in the blood (Greim et al., 
1995).  
Unfortunately, most of these efforts, while academically fulfilling, have left 
researchers with more questions than answers.  What is known about the 
mechanism of FB1 toxicity centers around its inhibitory effect on ceramide 
synthase. This inhibition of de novo ceramide production leads to a significant 
disruption in sphingolipid metabolism often causing a disruption in the 
sphinganine:sphingosine ratio which has been identified as a potential biomarker 
of fumonisin exposure (Cai et al., 2007).  While diagnostic in laboratory animals 
chronically exposed to fumonisin B1, changes in the sphingolipid ratio do not 
seem to be an effective means by which fumonisin exposure can be monitored 
in humans (Wild and Gong, 2010).  Species differences in toxicokenetics and 
toxicodynamics are most likely responsible for this incongruency.  Thus the need 
for sensitive, reliable, non species specific biomarkers of FB1 exposure still 
exists.  
Previously, montmorillonite clay was shown to reduce the amount of free 
FB1 in an aqueous environment and provide protection against the toxin’s effects 
in a hydra toxicity assay.  Although ferrihydrite (FH) was also able to sequester 
FB1, the long term effects of feeding an iron based material as an enterosorbent 
are not known.  Conversely, NovaSil is a calcium montmorillonite that has 
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previously been shown to be a safe and effective mycotoxin enterosorbent in 
animals and humans (Phillips et al., 2008).  While in vitro 
results from both sorbents were encouraging, this preliminary in vivo study 
focused only on smectite materials to verify previous findings and assess the 
potential of montmorillonite clay as an enterosorbent for FB1.  
  The Fischer 344 rat has been well established as an appropriate animal 
model for fumonisin toxicity studies (NTP, 2001; Cai et al., 2007).  The use of an 
animal model provides the appropriate bridge for translation of in vitro success 
into in vivo solutions.  The use of urinary FB1 as a biomarker of exposure has 
been previously demonstrated in Fischer 344 rats, and we hypothesized that this 
biomarker would be sufficiently sensitive to detect any reduction of FB1 
bioavailability due to NS treatment (Cai et al., 2007). 
O-phthalaldehyde (OPA) derivatization is currently considered the 
standard detection method for quantitative and qualitative measurement of FB1 
using HPLC.  While this method of derivatization offers many advantages, its 
disadvantages led us to consider the use of naphthalene 2,3 dicarboxaldehyde 
(NDA) as the derivatization agent in our analysis (Williams et al., 2004b; Cho et 
al., 2002; He et al., 2005).  NDA derivatization has previously demonstrated 
greater sensitivity in sphingolipid detection compared to OPA, and due to its 
stability, provided the opportunity for automation of our analysis procedure, 
which increased sample throughput without jeopardizing precision or accuracy.  
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 Therefore, the main objectives of this study were to evaluate the use of 
NDA derivatization versus OPA derivatization for detecting low concentrations of 
FB1, to adapt these analytical methods in the development of a sensitive and 
reliable method for the detection of urinary FB1, and to assess FB1 exposure and 
evaluate the ability of NS to reduce FB1 bioavailability in a Fischer 344 rodent 
model.    
 
3.1 Materials and methods 
3.1.1 Chemicals and reagents 
Fumonisin B1, o-phthalaldehyde (OPA), methanol, 2- mercaptoethanol, 
sodium phosphate dibasic  and phosphoric acid  were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO).  Naphthalene 2, 3-dicarboxaldehyde 
(NDA), potassium cyanide (KCN), sodium tetraborate (STB), phosphate buffered 
saline (PBS) and potassium hydroxide (KOH) were also obtained from Sigma. 
Fumonitest WB columns were purchased from VICAM (Watertown, MA, USA).  
All of the experiments were performed using filtered and deionized water (18.2 
MΩ.cm) (Millipore, Milford, MA), and all other chemicals and reagents were 
purchased commercially at the highest degree of purity available.  
 
3.1.2 Preparation of fumonisin B1 standard solution 
A 10 ppm FB1 standard was prepared in 50:50 methanol: water. FB1 
standards were prepared daily. 
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3.1.3 Preparation of mobile phase 
23:77 0.1M sodium phosphate: methanol mobile phase was prepared as 
described in the previous study. 
 
3.1.4 Preparation of o-phthalaldehyde solution 
O-phthaladehyde solution was prepared daily as described in the 
previous study. 
 
3.1.5 Preparation of naphthalene 2,3 dicarboxaldehyde  solution 
NDA solution was prepared as described by He et al. (He et al., 2005).  
Briefly, 3 ml of a 4% aqueous sodium tetraborate dibasic solution was added to 
17 ml of HPLC grade methanol and vortexed for 10 s.   Next, 200 μl of a 0.83 
mM aqueous KCN solution was added to the methanol/tetraborate solution.  
Then, 3.6 mg of naphthalene 2,3 dicarboxaldehyde was added to the solution 
and vortexed until dissolved (approx 3 m).  The prepared NDA solution was 
wrapped in foil and refrigerated until use.  The NDA derivatization agent was 
prepared daily. 
 
3.1.6 Comparison of OPA versus NDA derivatization sensitivity 
 Detection of both OPA and NDA derivitized FB1 was linear, with NDA 
having a lower limit of detection equal to 0.242 ng. The detected fluorescent 
intensity of NDA derivatized FB1 was two to five times the intensity of OPA 
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derivatized FB1 (Figures 23 and 24).  
 
3.1.7 Urinary FB1 rodent model experimental design   
Eighteen five -week-old male (110–130 g) Fisher 344 rats were 
purchased from Harlan (Houston, TX) and maintained on nutritionally complete 
powdered feed (Teklad rodent diet 8604, Harlan, Madison, WI) and water ad 
libitum. In this study, rats were randomly placed in 3 equal groups (A, B, C). The 
rats in group A and C were fed untreated basal rodent feed; the rats in group B 
received basal rodent feed containing 2% NS (w/w). After a brief acclimation 
period (1week), the rats were placed in metabolism cages (1 rat/cage) for 8 days 
and urine was collected. Rodents in groups A and B were administered FB1 at 
25 mg/kg b.w. or 3.75 mg of toxin (based on 150g body weight) via aqueous 
gavage.  Fischer rats from group C served as the absolute control group and 
were not exposed to FB1 or clay.   The dietary NS clay concentration was based 
on the highest level previously determined to be safe in a chronic rodent study 
(Afriyie-Gyawu et al., 2005). All rats were housed in a climate-controlled 
environment (temperature 22– 25 C°) that was artificially illuminated (12 hr 
dark/12 hr light) and free from chemical contamination.  Rats were inspected 
daily for general appearance, behavioral changes and signs of morbidity and 
mortality. Body weights were measured initially then twice per week throughout 
the course of the study.  Upon termination, organs were not collected because 
the short duration of the study and the relatively low FB1 dose selected were
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unlikely to produce remarkable pathology.  
 
3.1.8 Preparation of urine samples and urinary FB1 analysis 
Urine samples were stored at -80oC until analysis. Samples were thawed 
at room temperature and centrifuged at 500 g for 5 min. Samples (10 ml) were 
passed through Fumonitest WB columns (VICAM, Watertown, MA) at a flow rate 
of approximately 1 ml/min. Columns were washed with 10 ml phosphate 
buffered saline before elution with 2 ml 100% methanol. Samples were dried at 
50oC under nitrogen gas and reconstituted in 300 μl of 50:50 methanol:water. 
NDA solution (300 μl) was added to samples which were vortexed and heated 
(50oC) for 10 min (Cho et al. 2002). Analyte extracts were injected (150 μl) onto 
a 250 x 4.6 mm C-18 LUNA column, 5 μm particle size (Phenomenex, Torrance, 
CA) with mobile phase consisting of 77:23 methanol:sodium phosphate dibasic 
(0.1 M , pH 3.35) at a flow rate of 1 ml/min. FB1 analysis was performed using a 
Waters HPLC System equipped with an auto-injector (model 717A) and 
fluorescence detector (model 2475). Excitation and emission parameters were 
set at 335 and 440 nm, respectively, for detection of OPA-derivatized material, 
and at 252 and 483 nm, respectively, for detection of NDA-derivatized material. 
Creatinine concentrations in urine samples were measured at the Texas 
Veterinary Medical Diagnostic Lab in College Station, TX.  
87 
 
3.1.9 Statistical analysis 
 Data generated from HPLC analyses were transferred into an Excel 
database for management. Mean, median, confidence interval (CI) and range 
were calculated for concentrations of FB1. To show the consequence of NS 
ingestion on FB1 levels, statistical evaluation focused on the comparisons 
among different treatment groups at three different time points. Non-detectable 
samples = LOD/2 for statistical analysis. One way ANOVA and Fishers LSD 
were used to compare the differences among and between treatment groups. A 
p-value < 0.05 (two-tailed) was considered significant. Statistical analyses were 
done using SPSS software version 15.0 (SPSS Headquarters., Chicago, IL). 
 
3.2 Results 
3.2.1 Comparison of OPA versus NDA derivatization sensitivity 
 Detection of both OPA and NDA derivitized FB1 was linear, with NDA 
having a lower limit of detection equal to 0.242 ng. The detected fluorescent 
intensity of NDA derivatized FB1 was two to five times the intensity of OPA 
derivatized FB1 (Figures 23 and 24).  
 
3.2.2 Measuring FB1 exposure and NovaSil efficacy in a Fischer 344 rodent 
model 
 Urine samples were collected from 3 groups (A,B,C) of Fisher 344 rats for 
a duration of 8 days.  Only urine from days 1-4 were used in this analysis as the 
  
88 
Limit of detection comparison for OPA and NDA derivatization of 
FB1 
0.00E+00
2.00E+07
4.00E+07
6.00E+07
8.00E+07
1.00E+08
1.20E+08
483 241.5 48.3 9.66 4.83 0
Amount FB1 Detected (ng)
P
e
a
k
 
A
r
e
a
 
D
e
t
e
c
t
i
o
n
 
I
n
t
e
n
s
i
t
y
OPA 0.83mM NDA 0.83mM
 
Figure 23. Limit of detection comparison for OPA and NDA derivatization of FB1 (high concentration).  Detection      
intensity comparison of OPA derivatized FB1 vs. NDA derivatized FB1 at higher concentrations.
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Figure 24. Limit of detection comparison for OPA and NDA derivatization of FB1 (low concentration). Detection        
intensity comparison of OPA derivatized FB1 vs. NDA derivatized FB1 at low concentrations. 
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urinary FB1 biomarker was undetectable 3 days after mycotoxin ingestion.  Urine 
was collected at day 1 prior to gavage in groups A and B.  Rats in group A 
received 25 mg FB1/kg b.w. in a one time aqueous gavage at the end of day 1.  
Mean total urinary FB1 excretion for rats in group A was 86.5 ng FB1/ml urine on 
Day 2; on day 3, excretion was reduced to 18.3 ng FB1/ml urine.  Median values 
were similar at 89.2 and 18.4 ng FB1/ml urine on days 2 and 3, respectively.  
Creatinine standardized urinary FB1 for group A had a mean value of 194.1 ng 
FB1/mg creatinine on day 2 and 9.4 ng FB1/mg creatinine on day 3.  Median 
values were similar at 192.0 and 9.9 ng FB1/mg creatinine on day 2 and day 3, 
respectively.   
 Rats in group B received 25mg FB1/kg b.w. in a one time aqueous 
gavage while being maintained on control rodent feed supplemented with 2% 
NovaSil.  Mean total urinary excretion for rats in group B was 62.6 ng FB1/ml 
urine on day 2; on day 3 excretion was reduced to 8.3 ng FB1/ml urine.  Median 
values were similar at 59.0 ng FB1/ml urine on day 2 and 9.2 ng FB1/ml urine on 
day 3.  Creatinine standardized urinary FB1 for this group had a mean value of 
158.2 FB1/mg creatinine on day 2 and on day 3 excretion was only 4.4 ng 
FB1/mg creatinine. 
 Median values were similar at 154.3 ng FB1/mg creatinine for day 2 and 
5.0 ng FB1/mg creatinine on day 3.  Rats in group C were the absolute control 
group and were only fed control feed.  Urinary FB1 was not detected in this 
group (Figures 25 and 26; Table 7).  There was a statistically significant 
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Figure 25. Novasil reduction of total excreted urinary FB1 in Fischer 344 rats. 
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Figure 26. Novasil reduction of creatinine standardized urinary FB1 in Fischer 344 rats. 
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Data represent the mean, median, confidence interval (CI) and median from each 
treatment group 
* Indicates p< 0.05 compared to FB1 control group 
TABLE 7 
    
NovaSil reduction of urinary FB1 biomarker in Fischer 344 rats 
        
 
Absolute 
Control FB1 control 
FB1 + 2% NS 
treatment 
    
Urine Collection Day 2    
    
% detectable FB1 samples 0 (n=6) 100 (n=6) 100 (n=6) 
    
    
Mean FB1 (95% CI) N.D. 864.68 (719-1010.14) 
*625.77 (554.17-
696.83 
Median FB1 (ng/ ml urine) N.D. 892.35 590.41 
    
    
Mean FB1 (95% CI) N.D. 194.07 (161.55-226.59) 
*158.17 (138-21-
178.14) 
Median FB1 (ng/ mg 
creatinine) N.D. 191.95 154.32 
    
    
Urine Collection Day 3    
    
% detectable FB1 samples 0 (n=6) 100 (n=6) 100 (n=6) 
    
    
Mean FB1 (95% CI) N.D. 183.07 (110.16-255.98) 
*83.29 (18.40-
148.19) 
Median FB1 (ng/ ml urine) N.D. 183.65 91.92 
    
    
Mean FB1 (95% CI) N.D. 9.38 (6.03-12.72) *4.42 (1.00-7.85) 
Median FB1 (ng/ mg 
creatinine) N.D. 9.91 4.95 
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difference in the means between all three treatment groups.  Total urinary FB1 
was significantly reduced by 27.6% in the NS treatment group compared to the 
control group on day 2.  When standardized with creatinine, urinary FB1 was 
reduced by 19%.  By day 3 however, total urinary FB1 was significantly reduced 
by 54.5% in the NS treatment group compared to the control group.  When 
standardized with creatinine, urinary FB1 was reduced by 53%. 
 
3.3 Discussion and conclusions 
 Exposure to fumonisins through the diet is a problem for animals and 
humans.  Development of strategies to combat this problem requires sensitive 
and reliable methods to assess their efficacy before they can be used to aid 
affected populations.  In this study, we determined that naphthalene 2,3 
dicarboxaldehyde derivatization of FB1 was better suited to our project goals 
than OPA derivatization and this method was used to evaluate urinary FB1 as a 
biomarker of exposure.  Furthermore we utilized this analytical method and 
biomarker to evaluate the efficacy of NS in decreasing FB1 bioavailability in a 
rodent model.   
 Based on our initial work, NDA derivatization of fumonisin B1 was found to 
have a lower limit of detection when compared to the OPA derivatized product 
(Figure 27).  This was a significant finding since a lower limit of detection (LOD) 
allowed for a more reliable quantitation of FB1 exposure.  This lower LOD is 
possibly attributed to the difference in aromatic components of OPA and NDA, 
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Figure 27.  The reaction of the primary amine of FB1 with naphthalene 2,3 –dicarboxaldehyde.  (FB1 (A) and 
naphthalene 2,3 –dicarboxaldehyde (B)) The reaction occurs in the presence of potassium cyanide, forms the 1-
cyano-2 alkyl isoindol fluorescent product that is detected using high performance liquid chromatography  and 
fluorescence detection. 
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benzene and naphthalene, respectively.  Also, NDA has more delocalized 
electrons than OPA which produce a stable isoindole product compared to the 
OPA derivative.  Additionally, the increased electron count can be correlated to 
the amount of fluorescence produced by the derivatized product, or its quantum 
yield.  Assuming a set wavelength of light, excitation energy is spread over more 
electrons in NDA when compared to OPA.  This transfer of energy moves the 
delocalized electrons to an excited state, and in an effort to return to their natural 
lower energy state, they produce light and heat.  As energy can only be 
transferred, the energy levels of individual electrons in OPA will be greater when 
compared to the energy levels of individual electrons in NDA after excitation 
from a finite source of energy.  Assuming that the amount of energy converted to 
heat is directly related to the excited energy level of an electron (higher energy 
level = more vibration), the larger number of electrons in NDA resonating at a 
lower energy level will transfer less energy to heat than the smaller number of 
electrons in OPA resonating at a higher energy level; more energy will be given 
off as photons at a lower wavelength.  This explanation is further substantiated 
when comparing the quantum yield of benzene (0.053) to naphthalene (0.23) 
(Du et al., 1998).   
 OPA derivatization has been previously utilized as the standard detection 
method for FB1 in foodstuffs and urine (Williams et al., 2004b; Cai et al., 2007; 
Shephard et al., 2007; Wild and Gong, 2010).  While OPA derivatization offers 
advantages, including low cost, ease of use, relatively low toxicity, reproducible 
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results at ppm concentrations, and relatively short run times, disadvantages are 
evident.  It has been reported that OPA derivatization forms unstable FB1-OPA 
derivatives that must be analyzed in an especially short time frame for maximal 
results (~2min) (Williams et al., 2004b; Cho et al., 2002; He et al., 2005).  In 
addition, OPA derivatization tends to lose its ability to resolve low concentrations 
of FB1 as the concentrations decrease to the low ppb-ppt range (figure 24).  
Since OPA derivatization must take place immediately before HPLC analysis, 
this methodology eliminates the possibility of automation of the 
procedure, limiting the sample throughput per day.  Use of NDA was favored 
over OPA due to its increased stability and its increased fluorescent properties 
(Cho et al., 2002; He et al., 2005).    
 Shetty and Bhat first proposed a sensitive method for detecting 
FB1 in urine in 1998 (Shetty and Bhat, 1998).  Recently a method for the 
detection of free FB1 in urine was developed for humans using LC/MS.  Gong et 
al. developed and utilized this method to see if a there was a correlation 
between the consumption of tortillas suspected to contain FB1 and the levels of 
FB1 in the urine (Gong et al., 2008).  This study suggested a dosimetric 
relationship between tortilla consumption and urinary FB1 levels.  Cai et al. had 
previously demonstrated dose dependent excretion of FB1 in urine by rats 
exposed to FB1 (Cai et al., 2007).  One caveat of the Gong study was the lack of 
direct measurement of FB1 in the tortillas which translated to a lack of exposure 
assessment at the individual level.   These omissions lead to an inability to 
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definitively prove a causal relationship between the excreted levels of urinary 
FB1 and contaminated tortilla consumption.  For this reason urinary FB1 must be 
further validated for dosimetry before it will be fully accepted as a viable 
biomarker.  Urinary FB1, however, showed significant promise as a biomarker 
because of positive correlations to FB1 exposure in more than one species of 
interest. 
Detection and quantitation of fumonisin B1 from a matrix is most often 
accomplished by using chromatographic methods.  Analyses requiring high 
levels of sensitivity typically utilize high performance liquid chromatography 
(HPLC) coupled with absorbance or fluorescence detection or liquid 
chromatography mass spectrometry (LC-MS).  Because of the ability to verify 
the identity of an analyte based on mass/charge ratio, LC-MS (and variations of 
this configuration) are considered the gold standard.  LC-MS systems are 
expensive, however, often prohibitively so to the regions and populations that 
might most benefit from the technology.  For this reason, HPLC is often 
substituted for LC-MS offering similar sensitivity without the expensive start-up 
and maintenance costs.  HPLC offers an “affordable” option promoting 
sustainability in intervention situations with the ultimate goal of empowering 
affected populations to maintain progress. 
 Once a sufficient limit of detection was obtained (ppb/ppt), we used our 
HPLC method to measure the exposure to ingested FB1 in a rodent model using 
urinary FB1 as a biomarker. Urinary FB1 was detected in both groups that were 
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exposed to FB1 in this study.  Similar to previous studies, less than 1% of our 
FB1 dose was excreted in the urine.  FB1 is poorly absorbed from the GI tract 
and the majority of FB1 elimination occurs through the feces, either through non-
absorption or biliary excretion (Shephard et al., 1992a; Shephard et al., 1992b).   
All animals dosed with fumonisin B1 displayed the urinary FB1 biomarker within 
24 h.  In urine analyzed 48 h after gavage, the biomarker was reduced by almost 
80% and by 72 h, urinary FB1 was not detectable.  This 48 h window is similar to 
other urinary biomarkers of mycotoxin exposure (Wang et al, 2008).    
 A major objective of this study was the verification of in vitro sorption of 
FB1 by NovaSil, and evaluation of its ability to reduce bioavailability in vivo.  The 
ultimate goal of this evaluation was to decide whether NS, a safe and effective 
enterosorbent for aflatoxins, could confer protection on populations exposed to 
fumonisins through their diet.  NS is a calcium montmorillonite that has 
previously been shown to be safe and effective in reducing the bioavailability of 
ingested mycotoxins in animals and humans (Wang et al, 2008, Phillips et 
al.,2008). Additionally, montmorillonites have been shown in previous studies to 
sequester FB1 from aqueous solutions and protect hydra from the toxic effects of 
FB1 exposure.  In this study, NovaSil was able to significantly reduce total 
urinary FB1 by 27.6% in the NS treatment group compared to the control group 
on day 2.  When standardized with creatinine, urinary FB1 was reduced by 
almost 20%.  The reduction of FB1 bioavailability was even greater on day 3 as 
total urinary FB1 was significantly reduced by 54.5% in the NS treatment group
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 compared to the control group.  When standardized with creatinine, urinary FB1 
was reduced by 53%.  This enhanced reduction was probably a function of 
concentration dependent urinary FB1 excretion on day 3 due to concentration 
dependent metabolism and release from storage organs, plasma, and bile that 
could potentially act as multipliers of urinary FB1 excretion in the control group. 
This reduction could also be an artifact of the larger variation at the lower 
biomarker levels. Further study is warranted to further examine these effects and 
the efficacy of montmorillonite as a fumonisin enterosorbent. Based on the 
results of this study, urinary FB1 was found to be a sensitive biomarker of 
fumonisin exposure that can be analyzed using NDA derivatization, HPLC 
separation and fluorescence detection methods.  Additionally, NS has 
demonstrated an ability to reduce FB1 bioavailability in an animal model.  This 
effect is significant as literature suggests that populations are co-exposed to 
aflatoxins and fumonisins from their diet.  A multifunctional enterosorbent that 
could sorb both mycotoxins simultaneously would be of great benefit to public 
health. 
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CHAPTER IV 
SURVEY OF FB1 EXPOSURE AND EFFECTS OF NOVASIL IN A GHANAIAN 
POPULATION 
 
Fumonisin B1 (FB1) is the most abundant of the naturally occurring 
fumonisins, a group of mycotoxins produced by Fusarium fungi. FB1 has been 
shown to be hepatotoxic, nephrotoxic, and carcinogenic in a number of species 
(Voss et al., 2002). Epidemiological studies have correlated Fusarium spp. and 
fumonisin contamination of food sources with increased incidences of 
esophageal cancer in regions of China and South Africa, neural tube defects 
along the Texas-Mexico border, and primary liver cancer in China (Marasas et 
al., 2004; Shephard et al., 2007a; Shephard et al., 2007b; Chu et al., 1994; 
Ueno et al., 1997). Currently, there are no reports describing the metabolism or 
kinetics of FB1 in humans that definitively demonstrate a causative relationship 
(Stockmann-Juvala et al., 2008). While methods assessing the hazard of 
fumonisins in foodstuffs exist, few are capable of determining the actual 
exposure of populations considered to be “at risk” (Shephard et al., 1996; 
Shephard et al., 2007b).   
Changes in sphingolipid ratio due to the inhibitory effect of FB1 on the de 
novo ceramide synthase activity are commonly utilized as biomarkers for FB1 
exposure (Voss et al., 2002; Sadbourdy et al., 2008; He et al., 2006). Alterations 
in the sphinganine:sphingosine ratio have accurately reflected fumonisin 
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exposure in some lab animal species, but have not been shown to be consistent 
indicators of exposure in human populations consuming fumonisin-contaminated
 foods (Solfrizzo et al., 2004; Abnet et al., 2001). Metabolic studies in non-
human primates and swine have shown that excretion of FB1 is mainly through 
the feces with <1% urinary excretion (Shephard et al., 1994; Fodor et al., 2008). 
Due to high dietary levels of FB1 in developing countries, urinary biomarkers 
have been successfully used to characterize exposure in human populations 
(Gong et al., 2008). These same biomarkers can be applied to evaluate 
intervention strategies that could reduce exposure to fumonisins. (Shetty and 
Bhat 1998;Turner et al.; 1999; Gong et al.; 2008) 
Our laboratory has previously reported that a Ghanaian population is 
highly exposed to aflatoxins (AFs) due to the frequent consumption of AF-
contaminated foods (Jolly et al. 2006, Wang et al. 2008, Phillips et al. 2008, 
Williams et al. 2004a). It has been well-documented that aflatoxins cause 
immunosuppression, malnutrition, and hepatocellular carcinoma (Williams et al. 
2004, Wogan 1992). Among a variety of strategies that have been reported to 
reduce AF exposure, the use of NovaSil (NS), a dioctahedral smectite clay, as a 
primary intervention for the enterosorption of toxin has been shown to be safe 
and effective in humans (Phillips et al. 2008).  
In vitro and in vivo studies have demonstrated that FB1 can potentiate the 
effects of AFs (McKean et al. 2005). Kpodo et al. verified the co-occurrence of 
Fusarium spp. and fumonisins with AFs in maize samples from Ghanaian 
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markets (Kpodo et al. 2000).  It was postulated that participants from our 
previous study in Ghana, shown to be at high risk for aflatoxicosis, may be co-
exposed to fumonisins. Thus, the main objectives of this study were to apply a 
sensitive, cost-effective, and reliable method for the detection of urinary FB1, to 
assess exposure to fumonisins in a Ghanaian population highly exposed to AFs 
using the FB1 urinary biomarker; and assess the efficacy of NS clay to reduce 
fumonisin exposure. Importantly, strategies that reduce co-exposures to AFs 
and fumonisins are highly desirable for populations at risk for both agents. 
 
4.1 Materials and methods 
4.1.1 Chemicals and reagents 
Fumonisin B1, methanol, 2- mercaptoethanol (cas # 60-24-2), sodium 
phosphate dibasic and phosphoric acid were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO).  Naphthalene 2, 3-dicarboxaldehyde (NDA), 
potassium cyanide (KCN), sodium tetraborate (STB), phosphate buffered saline 
(PBS) and potassium hydroxide (KOH) were also obtained from Sigma. 
Fumonitest WB columns were purchased from VICAM (Watertown, MA, USA).  
All of the experiments were done using filtered and deionized water (18.2 
MΩ.cm) (Millipore, Milford, MA), and all other chemicals and reagents were 
purchased commercially at the highest degree of purity available.  
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4.1.2 Preparation of fumonisin B1 standard solution  
A 10 ppm FB1 standard was prepared in 50:50 methanol:water. 
Naphthalene 2,3-dicarboxaldehyde (NDA) solution was prepared daily using 
methods previously described. 
 
4.1.3 Preparation of mobile phase 
23:77 0.1M sodium phosphate: methanol mobile phase was prepared as 
described in the previous study. 
 
4.1.4 Preparation of naphthalene 2,3 dicarboxaldehyde solution 
NDA solution was prepared daily as described in the previous study. 
 
4.1.5 Preparation of urine samples and Ghanaian urinary FB1 analysis 
Urine samples were stored at -80oC until analysis. Samples were thawed 
at room temperature and centrifuged at 500 g for 5 min. Samples (10 ml) were 
passed through Fumonitest WB columns (VICAM, Watertown, MA) at a flow rate 
of approximately 1 ml/min. Columns were washed with 6 ml phosphate buffered 
saline and 6ml water before elution with 2 ml 80% methanol. Samples were 
dried at 50oC under nitrogen gas and reconstituted in 150 μl of 50:50 
methanol:water. Aliquots of NDA solution (300 μl) were added to samples which 
were vortexed and heated (50oC) for 10 min (Cho et al. 2002). Analyte extracts 
were injected (200 μl) onto a 250 x 4.6 mm C-18 LUNA column, 5 μm particle 
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size (Phenomenex, Torrance, CA) with mobile phase consisting of 77:23 
methanol: sodium phosphate dibasic (0.1 M , pH 3.35) at a flow rate of 1 ml/min. 
FB1 analysis was performed using a Waters HPLC System equipped with an 
auto-injector (model 717A) and fluorescence detector (model 2475). Excitation 
and emission parameters were set at 252 and 483 nm for detection of NDA-
derivatized material. Creatinine concentrations in urine samples were measured 
at St. Joseph’s Regional Health Center Laboratory in Bryan, TX.  
 
4.1.6 Urinary FB1 MALDI-TOF mass spectrometry 
The identity of the derivatized urinary FB1 metabolite was confirmed via 
MALDI-TOF on a Kratos Kompact Probe MALDI-MS instrument (Kratos 
Analytical). A saturated solution of alpha-cyano-4-hydroxycinnamic acid (in 
methanol) was used to facilitate ionization of the sample as previously described 
by Neupert et al. (Neupert et al., 2009).    
 
4.1.7 Study site and population  
Stored urine samples were available from our previous Phase IIa clinical 
trial assessing the safety and efficacy of NovaSil for reducing AF exposure in a 
Ghanaian population (Phillips et al., 2008). Volunteers were recruited from six 
communities within the Ejura-Sekyedumase district in the Ashanti Region of 
Ghana. Biomarker data regarding exposure to fumonisins was unknown for this 
area; however, maize samples had been shown to contain fumonisins (Kpodo et 
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al., 2000). To our knowledge, this was the first study to measure FB1 in a human 
population in Ghana. A total of 180 volunteers (male and female) were selected 
to participate in the NS intervention study based on predetermined inclusion 
criteria. Participants met the following conditions: signed consent form, healthy 
status based on physical examination, age 18-58 years, intake of corn and/or 
groundnut-based foods at least four times per week, blood AFB1-albumin adduct 
levels > 0.5 pmol AFB1/mg albumin, no history of chronic disease(s), no use of 
prescribed medications, non-pregnant and non-breastfeeding females, normal 
ranges of hematological parameters, normal liver and renal function indicators 
(blood and urine parameters).   
 
4.1.8 Study design and protocol 
 The study protocol was approved by the Institutional Review Boards at 
Texas A&M University and Noguchi Memorial Institute for Medical Research in 
Ghana for Ethical Clearance. All participants were provided written informed 
consent, as well as an oral explanation prior to beginning the study. The overall 
study design adhered to guidelines set for a randomized, double-blind, placebo 
controlled Phase IIa clinical trial (Sangare-Tigori et al., 2006). Participants were 
randomly divided into one of the three groups: High dose (NS 3.0 g/day), low 
dose (NS 1.5 g/day) or placebo control (microcrystalline cellulose) for a period of 
3 months. Trained study monitors collected blood and urine samples from each 
participant at multiple time points. Aliquots of the first urines were stored 
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separately in polypropylene tubes and shipped frozen to Texas A&M University 
where they were stored at -80°C prior to biomarker analysis. Samples collected 
at week eight and ten from all three treatment groups (186 samples) were used 
in this preliminary study to assess fumonisin exposure and intervention efficacy.  
 
4.1.9 Statistical analysis 
 Data generated from HPLC analyses were transferred into an Excel 
database for management. Mean, median, confidence interval (CI) and range 
were calculated from analysis of FB1. To show the consequence of NS ingestion 
on FB1 levels, statistical evaluation focused on the comparisons among different 
treatment groups at two different time points. Non-detectable samples = LOD/2 
for statistical analysis. Since the parameters were not normally distributed, the 
Kruskal-Wallis test and Wilcoxon rank sum test was used to compare the 
differences among and between treatment groups. A p-value < 0.05 (two-tailed) 
was considered significant. Statistical analyses were done using SPSS software 
version 15.0 (SPSS Headquarters., Chicago, IL). 
 
4.2 Results 
4.2.1 Ghanaian exposure assessment using urinary FB1 
 Urine samples (186) from study participants at week 8 and week 10 were 
analyzed for the presence of FB1 using immunoaffinity clean-up and HPLC 
analysis. Chromatograms of NDA derivatized FB1 standard, spiked human urine 
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and a representative urine sample from a study participant were compared for 
continuity (Figure 28). Mean and median levels of FB1 are presented in Table 8. 
In the week 8 placebo treatment group (n = 23), 14 samples (60.9 %) were 
found to be positive for the presence of FB1 with a mean urinary FB1 
concentration of 7.12 ng/mg creatinine. In the week 10 placebo group (n = 43), 
the percentage of samples with detectable FB1 was higher (72.1%), but the 
mean urinary concentration of 6.29 ng FB1/mg creatinine was similar to week 8.  
Analysis of the week 8 high dose (n = 23) and low dose (n = 22) NS treatment 
groups revealed a lower percentage of participants with detectable urinary FB1 
(39.1 and 45.5%, respectively). Week 10 high (n = 35) and low dose (n = 40) 
treatment groups also displayed a reduction in the percentage (54.3 and 52.5 %, 
respectively) of urinary samples with detectable FB1 along with decreased FB1 
levels of 1.02 and 1.69 ng/mg creatinine, respectively. A similar trend was 
observed in the treatment groups from both week 8 and 10 when comparing 
non-creatinine adjusted urinary FB1 levels.  Because the FB1 data was not 
normally distributed, non-parametric analysis was applied for all statistical 
evaluations.  
  Median FB1 levels for the high dose treatment group were significantly 
lower (p < 0.05) than the placebo group at week 8.  FB1 levels from both 
treatment groups, high and low dose, were significantly reduced compared to 
placebo at week 10 (Figure 29, Table 8). 
  
109 
 
 
 
Figure 28. A. HPLC chromatogram of NDA derivatized FB1 standard (retention time ~21.5 min).  B. HPLC chromatogram of 
spiked human urine (retention time ~21.5 min) and a representative urine sample from a study participant containing NDA 
derivatized FB1 (red) (retention time ~21.5 min). 
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Figure 29. Distribution of total urinary FB1 between treatment groups at weeks 8 and 10 
(ng FB1/ml urine).  Data represents the distribution of FB1 in the various treatment 
groups based on a NovaSil intervention in Ghana. Extreme outliers are not depicted. 
There was a statistically significant difference among treatments (p<0.05). There was a 
significant difference between the median FB1 levels in the NS treated groups versus the 
placebo group (p<0.05). There was not a significant difference between median FB1 
levels in the high and low dose groups (p = 0.566). 
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TABLE 8 
 
Reduction of FB1 with NovaSil Treatment in a Ghanaian population 
 
 
                             
                             NovaSil Treatment                                          Control 
 
       
 High Dose  Low Dose  Placebo 
  (3.0 g/Day)  (1.5 g/Day)  (1.5 g/Day) 
Week 8 Urinary FB1 analysis       
       
       
% detectable  FB1 samples  39.1 (9/23)  45.5 (10/22)  60.9 (14/23) 
       
Mean FB1  (95% CI) 
Median FB1 (ng/ml urine) 
 
 
*4.05 (0.99 – 7.10) 
0.19 
 
 
 
5.61 (1.74 – 9.48) 
0.19 
 
 
 
9.36 (4.51 – 14.22) 
5.45 
 
Mean FB1  (95% CI) 
Median FB1 (ng/mg creatinine) 
 
 
*1.07 (0.22 – 1.91) 
0.20 
 
 
 
5.61 (0.81 – 10.42) 
0.20 
 
 
 
7.12 (1.69– 12.52) 
2.00 
 
       
Week 10 Urinary FB1 analysis       
       
% detectable  FB1 samples  54.3 (19/35)  52.5 (21/40)  72.1 (31/43) 
       
Mean FB1  (95% CI) 
Median FB1 (ng/ml urine) 
 
 
*0.81 (0.53 – 1.09) 
0.44 
 
 
 
*0.73 (0.37 – 1.08) 
0.21 
 
 
 
5.03 (3.76 – 6.30) 
5.45 
 
Mean FB1  (95% CI) 
Median FB1 (ng/mg creatinine) 
 
 
*1.02 (0.45 – 1.59) 
0.28 
 
 
 
*1.69 (0.51 – 2.87) 
0.20 
 
 
 
6.29 (3.75– 8.84) 
2.91 
 
 
Data represent the mean, confidence interval (CI) and median from each treatment group 
Placebo = microcrystalline cellulose 
*Indicates p < 0.05 compared to placebo group 
112 
 
   Mean urinary FB1 was reduced >40% in the NS low and high dose 
treatment groups at week 8 and > 80% at week 10. Similar results were seen 
after creatinine standardization for urine volume (Figure 30, Table 8).  Mean 
urinary FB1 was reduced >80% in the high dose treatment groups at both week 
8 and 10.  There was also a 73% reduction in mean urinary FB1 in the low dose 
treatment group at week 10. Although dose-dependent differences in FB1 
median levels between the high and low dose treatment groups were not found 
to be statistically significant, these results suggest a high affinity of the NS clay 
for FB1.   
 
4.2.2 MALDI-TOF analysis of urinary FB1 
 MALDI-TOF mass spectrometry (MTMS) analysis of parent (M+H+), NDA 
derivatized, and a NDA derivatized + sodium ion (M+Na+) confirmed a 
mass/charge of 723.0, 906.5, and 928.3, respectively (Figure 31A-C). MTMS 
analysis of FB1 peaks collected from HPLC analysis of randomly selected 
positive urine samples verified the presence and identity of FB1, with peaks at 
907.4 (M+H+) and 928.5 (M+Na+) (Figure 31C). Worth noting, is the lack of 
parent peak (~722.8) in MTMS analyzed samples which may provide an indirect 
indicator of the efficiency of the NDA derivatization reaction.  
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Figure 30. Distribution of creatinine standardized urinary FB1 between treatment groups 
at weeks 8 and 10 (ng FB1/mg creatinine).  Data represents the distribution of FB1 in the 
various treatment groups based on a NovaSil intervention in Ghana. Extreme outliers are 
not depicted. There was a statistically significant difference among treatments (p<0.05). 
There was a significant difference between the median FB1 levels in the NS treated 
groups versus the placebo group (p<0.05). There was not a significant difference 
between median FB1 levels in the high and low dose groups (p = 0.955).
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Figure 31.  MALDI-TOF mass spectra of parent and derivatized FB1(MS).  MS are 
based on relative intensity (y-axis) of depicted peaks (highest peak = 100%). A. MS of 
underivatized standard FB1 in water (723 m/z).  B. MS of NDA derivatized FB1 from 
spiked urine sample (~906.1 m/z) and NDA derivative + Na ion (~928 m/z). C. MS of a 
representative FB1 positive participant urine sample verifying presence of FB1.  
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4.3 Discussion and conclusions 
Human exposure to multiple mycotoxins has received increased attention, 
and recent studies in West Africa have confirmed the co-occurrence of AFs and 
fumonisins in foodstuffs found in Cote d’Ivoire and Ghana (Kpodo et al. 2000, 
Sangare-Tigori et al. 2006). Surveys have demonstrated that maize-based 
products are often co-contaminated with diverse mycotoxins; however, there is a 
paucity of published data measuring human exposure to fumonisins and AFs. 
Use of urinary FB1 as a biomarker of exposure in humans was first proposed by 
Shetty and Bhat in 1998 (Shetty and Bhat 1998). In 1999, Turner et al. reported 
that analysis of urinary FB1 held significant promise as there was a need for a 
reliable biomarker of exposure to fumonisins (Turner et al. 1999).  A recent study 
by Gong et al. demonstrated a dose-response relationship between 
consumption of tortillas containing fumonisins and human urinary FB1 (Gong et 
al. 2008).  In our study, biomarker data in humans from Ghana support the work 
by Gong et al. in Mexico. Moreover, these same data shows that NS clay is able 
to mitigate FB1 exposure from the diet possibly by diminishing the bioavailability 
of this mycotoxin in the gastrointestinal tract.    
The week 8 and 10 mean FB1 levels measured in our study population 
(9.36 and 5.03 ng FB1/ml urine, respectively) were higher than mean urinary FB1 
concentration reported previously in Mexico (0.147 ng FB1/ml urine) (Gong et al. 
2008).
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Based on ~1% urinary excretion, an estimated metabolic rate of 1500 ml 
urine/day and the average size of an adult (70kg), it can be estimated that the 
exposure to FB1 at week 8 was 20.06 μg/kg b.w./day and 10.78 μg/kg b.w./day 
at week 10 in our placebo groups (Shephard et al. 1994, Fodor et al. 
2008). These values are higher than the FB1 levels reported from Mexico (0.368 
μg/kg b.w./ day) (Gong et al. 2008). A number of possible explanations may 
account for this difference in the levels of FB1 observed in humans in Ghana 
versus Mexico. These include variations in: (1) corn production techniques, (2) 
climate, (3) analytical methodologies, (4) maize preparation, processing, and 
amount consumed, (5) age, health, nutritional status, gender and (6) fumonisin 
metabolism due to population genetic polymorphisms. Furthermore, a market 
survey in Ghana detected levels of FB1 between 70 and 2621 (mean 608.8) 
µg/kg in maize intended for human consumption (Jolly et al. 2006). Based on an 
average maize intake of 369.5 g/day (MacIntyre et al. 2002), a 1% carryover of 
FB1 from the diet, and an average urinary excretion (1500 ml), Ghanaians from 
our site could potentially excrete urinary FB1 levels between 0.172 to 6.46 ng/ml 
urine. Mean Biomarker levels measured in this preliminary study are similar to 
this range.          
In the previous clinical trial in Ghana, significant decreases in median 
urinary aflatoxin M1 levels were observed at 12 weeks after NS intervention (p = 
0.0445) (Wang et al. 2008). Since samples that were collected at 12 weeks were 
depleted for aflatoxin biomarker analysis, we utilized the remaining samples at 
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the closest time points during the intervention (week 8 and 10), in order to 
assess the effect of NS treatment on urinary FB1 levels. Following treatment with 
NS, the week 8 samples had mean values of 4.05 and 5.61 ng/ml urine in the 
high and low dose treatment groups respectively.  At week 10 samples had 
further reduced mean values of 0.81 and 0.72 ng FB1/ml urine in the high and 
low dose treatment groups, respectively, versus 5.03 ng FB1/ml urine in the 
placebo group. Further studies are warranted to establish whether a temporal 
relationship exists allowing NS treatment to exert more effect at later time points.  
Based on these 10 week mean urine values, exposure could be estimated at 
1.72 and 1.54 μg/kg b.w./day for the high and low dose participants, 
respectively.  Following consumption with NS, participant exposure to FB1 was 
reduced below the JECFA provisional maximum tolerable daily intake for FB1 of 
2 μg/kg b.w./day (WHO 2002).  
Based on our previous research, NS clay has displayed: 1) favorable 
thermodynamic characteristics of  aflatoxin sorption,  2) tolerable levels of 
priority metals, dioxins/furans and other hazardous contaminants, 3) safety and 
efficacy in multiple animal species and humans, 4) safety and efficacy in long-
term animal studies, and 5) negligible interactions with vitamins, iron and zinc 
and other micronutrients.  Studies in vitro with NS clay have suggested that it 
sorbs aflatoxins and similar congeners with stereo- and regiospecificity.  A 
potential chemical reaction that may explain the high capacity and affinity of 
aflatoxins for clay surfaces is an electron donor-acceptor mechanism.  This 
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mechanism involves sharing electrons from the negative surface of the clay with 
partially positive atoms in the β-dicarbonyl system in the aflatoxins.  Moreover, 
animal studies have confirmed the preference of NS clay for aflatoxins, in that 
NS in the diet did not protect animals from the effects of other structurally 
diverse mycotoxins, including zearalenone, deoxynivalenol, T-2 toxin, ochratoxin 
A, cyclopiazonic acid, and ergotamine (Phillips et al., 2008).   
Dioctahedral smectite clays, including NS, have been evaluated in vitro 
for FB1 sorption and found to interact with this mycotoxin at interlayer surfaces 
(Lemke 2000). As previously stated, the potential mechanism for FB1 sorption by 
NS is protonation of the amino group at C2 on the molecule.  The charged FB1 
may facilitate a cationic exchange reaction at negatively charged surfaces of the 
clay similar to the interaction(s) of cationic surfactants or quaternary amines at 
interlayer surfaces in common dioctahedral smectite clays.  Further work is 
warranted to delineate the molecular mechanism and surface chemistry involved 
in the sorption process of FB1 onto NS and to confirm the efficacy and safety of 
NS clay as a multifunctional intervention for aflatoxins and fumonisins in animals 
and humans. 
Mycotoxins have been linked to death and disease, with an estimated 4.5 
billion people highly exposed in developing countries (Williams et al. 2004a). 
The mycotoxin problem to public health is longstanding, unavoidable, and 
seemingly inextricable.  Frequent and concurrent exposure to aflatoxins and 
fumonisins may enhance/synergize the toxic, carcinogenic, and teratogenic 
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effects of these food-borne contaminants. This study is the first to demonstrate 
the efficacy of enterosorbent intervention for FB1 exposure using HPLC with 
NDA derivitization to detect fumonisin biomarkers in human urine. Importantly, it 
also illustrates that a population in Ghana co-exposed to aflatoxins and 
fumonisins may be protected from the adverse effects of these mycotoxins using 
NS clay. As a primary intervention, capsules or other dose forms of NS could be 
used in clinical practice for both “acute emergencies” and “chronic exposures.” 
Additional studies are planned to confirm these findings in long-term clinical 
intervention trials in Ghana. Clay-based enterosorbent strategies represent a 
novel approach to the problem in populations that are at high risk for 
mycotoxicosis.  
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
  
Fumonisins contaminate the diet of a large proportion of the world’s 
population with as many as 4.5 billion people at risk for mycotoxicosis.  
Fumonisin toxicosis is a problem in developed regions but more so in 
developing regions where these mycotoxins affect staple foods, such as maize 
(corn) and other cereals.  Exposures to fumonisins are responsible for the 
development of equine leukoencephalomalacia, porcine pulmonary edema, and 
neoplasm formation in the liver and kidneys of rodents.  Exposure to fumonisin 
toxins are also highly correlated with increased incidences of esophageal and 
hepatic carcinomas in humans and are thought to be a major contributor to the 
global incidence of neural tube defects.  Fumonisin B1 exerts its effects through 
the competitive inhibition of de novo ceramide production which results in 
disruption of most, if not all, cellular processes.   
 Global public health organizations have tried to limit exposure to 
fumonisins and other mycotoxins to levels where the public health risk was 
minimal.  These recommendations are based on in vitro and in vivo data from 
mycotoxin studies, epidemiological studies in populations perceived to be 
exposed, and socioeconomic pressures.  It is this last variable that leads to 
large discrepancies in regulatory levels; one organization is focused on the 
elimination of all risk while another regulatory agency proposes levels that are 
deemed achievable and sustainable with the use of good agricultural and good 
manufacturing practices.  There have been difficulties in establishing guidelines 
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for public exposure to mycotoxins in which co-exposure is the driving force for 
regulation.  The scientific basis for previous mycotoxin regulations has been the 
study of these toxins and their effects in isolation, unknowingly, but likely to the 
detriment of public health. 
 Adding to this epidemic is the fact that the exposures and co-exposures 
to mycotoxins have largely been ignored as a public health concern.  Despite 
occasional high profile incidents such as acute poisoning outbreaks or the 
presence of mycotoxins in nutritional supplements, mycotoxins have not been 
widely prioritized from a public health perspective in low-income countries. 
Where attention has been paid, it is perceived to have been largely driven by 
the need to meet stringent import regulations on mycotoxin contamination in the 
richer nations of the world rather than to protect the population producing and 
consuming the contaminated crops locally. 
Recently there has been a shift in research focus from identification and 
study of mycotoxins such as fumonisin B1 in isolation to studies where their co-
existence with other mycotoxins such aflatoxin B1 are targeted.  Mycotoxins 
rarely exist in isolation in nature and the implications of co-exposure in “at risk” 
populations are of significant concern.  Fumonisin B1 and aflatoxin B1 have 
been shown to be synergistic in the formation of hepatic neoplasms.  While a 
few studies have examined the hazard of co-exposure to these potent 
mycotoxins, to date, there are no studies that have assessed the actual co-
exposure to these toxins in “at risk” populations and their resulting effects on 
public health.  This is due largely to the lack of reliable methods to assess the 
concurrent individual exposure to these toxins.  In an effort to reduce the 
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potential for exposure, intervention strategies have been proposed at the pre 
and post harvest level.  However, much like previous exposure assessments, 
these remediation strategies disregard the co-existence and co-exposure of   
populations at high risk for multiple mycotoxins.  
 As previously stated, regulatory mandates and recommendations exist 
for animal and human exposure to fumonisins in developed and developing 
parts of the world.  The impetus for compliance with these regulations is more 
likely a function of socioeconomic status than concern for well-being when 
poorer countries are compared to more developed nations.  Often the regions 
that would benefit most from concerted efforts of regulation and remediation of 
mycotoxin exposure are the regions least adapted to do so. Socioeconomic 
conditions often force the citizens of less developed countries to consume 
whatever is grown regardless of the condition.  Economically sensitive, yet 
culturally acceptable solutions for reducing exposure to mycotoxins like 
fumonisin B1 are in high demand. 
 Our studies were designed to adapt existing technology for the purpose 
of identification, quantitation, and remediation of fumonisin exposure in  
populations frequently exposed to mycotoxins.  Montmorillonite clays such as 
NovaSil are safe, inexpensive and represent a remediation strategy that is 
culturally accepted in many parts of the world.  Isothermal analyses were used 
to evaluate the binding capacity of a negatively charged sorbent 
(montmorillonite) and a positively charged sorbent (ferrihydrite). The results 
from these in vitro studies demonstrate that montmorillonite clays and 
ferrihydrite were able sequester fumonisin B1 from an aqueous environment and
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 protect lower organisms from the effects of toxicity.  Montmorillonite had a 
greater capacity for sorption of fumonisin B1 based on Qmax values.  In this 
case, the basis of this efficacy is probably the interaction of the positively 
charged amine and negatively charged interlayer that results from the 2:1 
dioctahedral structure of the clay.  This was indirectly confirmed by the lack of 
binding by a montmorillonite in which the interlayer had been collapsed using 
heat. In ferrihydrite, it is possible that the negatively charged acid groups on 
deprotonated fumonisin interacted with the positive surface charge of the 
sorbent.  Questions about the bioavailability of iron from chronic ferrihydrite 
treatment and the potential development of hemosiderosis and 
hemochromatosis were of concern and warrant further study.  Previous studies 
have shown, however, that montmorillonite clays such as NovaSil, are non-toxic 
at levels up to 2% w/w and were effective in aflatoxin sorption in rodent assays.  
For this reason, NovaSil was selected for in vivo studies to assess its potential 
as an enterosorbent for fumonisin exposure.   
 A critical barrier to the assessment of NovaSil as an enterosorbent was 
the lack of a sensitive yet reliable method of assessing levels of fumonisin B1 
bioavailability.  Fumonisins require conjugation to a fluorescent molecule in a 
process known as derivatization before they can be analyzed using HPLC.  O-
phthalaldehyde (OPA) and naphthalene 2, 3 dicarboxaldehyde (NDA) were 
compared as potential derivatization agents for FB1.  Derivatization of FB1 with 
NDA was found to produce an isoindole product that was stable and displayed 
a higher fluorescent intensity than the OPA derivatized product.  This could be 
due to increased numbers of delocalized electrons in NDA allowing for greater
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 molecular stability and increased quantum yield.   Through the use of 
naphthalene 2,3 dicarboxaldehyde derivatization, an HPLC method was 
adapted to the task of assessing fumonisin B1 exposure.  This method was 
critical as the validity of previous methods in assessing fumonisin B1 exposure 
were heavily dependent on the species studied (ie. sphinganine: sphingosine 
ratio in rodents).   In this work, urinary FB1 was shown to be a reliable 
biomarker of fumonisin B1 exposure in a Fischer 344 rodent model, confirming 
previous reports in the literature.  This biomarker reached it peak intensity 
within 24 hours of ingestion and was not detectable 72 hours after exposure.  
These results suggest that urinary FB1 is a short term biomarker offering a 
window of exposure assessment of only 48 hours.    
This short term biomarker was the cornerstone of our efforts to assess 
the efficacy of NovaSil as a fumonisin enterosorbent.  There was a significant 
reduction in fumonisin B1 bioavailability in the animals treated with NovaSil, 
confirming the results of our in vitro studies.  Despite our success, further 
studies are warranted to further assess potential species differences in the 
dosimetry of this biomarker.   
 Utilizing urinary FB1 as a short term biomarker, a sub-set of a Ghanaian 
population known to be exposed to aflatoxin B1 was found to be co-exposed to 
fumonisin B1.  This was noteworthy due to the known synergistic effects of co-
exposure to these mycotoxins.  In participants treated with NovaSil clay, urinary 
FB1 was reduced in a dose dependent fashion similar to the reduction seen in 
aflatoxin M1 biomarker.   No adverse effects from the ingestion of NovaSil were 
noted.  To our knowledge, this is the first report of co-exposure to fumonisin B1 
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and aflatoxin B1 and successful application of a multifunctional remediation 
strategy. Techniques described in this document are currently being adapted in 
Ghana in hopes that the progress gained will be sustained and used to enhance 
public health in the Region. 
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